{"questions": [{"body": "Which antibody is implicated in the Bickerstaff's brainstem encephalitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25379047", "http://www.ncbi.nlm.nih.gov/pubmed/23927937", "http://www.ncbi.nlm.nih.gov/pubmed/22698187", "http://www.ncbi.nlm.nih.gov/pubmed/21631649", "http://www.ncbi.nlm.nih.gov/pubmed/23275783", "http://www.ncbi.nlm.nih.gov/pubmed/19664367"], "ideal_answer": ["The syndrome defined by Bickerstaff of progressive, external ophthalmoplegia and ataxia, with disturbance of consciousness or hyperreflexia, has subsequently been associated with antiganglioside antibody, anti-GQ1b"], "exact_answer": [["antiganglioside antibody"]], "type": "factoid", "id": "56c1f039ef6e394741000052", "snippets": [{"offsetInBeginSection": 140, "offsetInEndSection": 406, "text": "In addition, BBE and Fisher syndrome, which are clinically similar and are both associated with the presence of the immunoglobulin G anti-GQ1b antibody, represent a specific autoimmune disease with a wide spectrum of symptoms that include ophthalmoplegia and ataxia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379047", "endSection": "abstract"}, {"offsetInBeginSection": 303, "offsetInEndSection": 503, "text": "The syndrome defined by Bickerstaff of progressive, external ophthalmoplegia and ataxia, with disturbance of consciousness or hyperreflexia, has subsequently been associated with anti-GQ1b antibodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23927937", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 386, "text": "An anti-GQ1b antibody syndrome has been proposed to underlie the common pathophysiology for the three disorders; however, other studies have found a positive anti-GM1 instead of anti-GQ1b antibody.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22698187", "endSection": "abstract"}, {"offsetInBeginSection": 775, "offsetInEndSection": 951, "text": "Serologic analysis of antibodies against ganglioside complexes (anti-GDIa, anti-GDIb, anti-GM1, anti-GM2, anti-GM3, anti-GQIb and anti-GTIb antibodies) showed negative results.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22698187", "endSection": "abstract"}, {"offsetInBeginSection": 1131, "offsetInEndSection": 1299, "text": "However, contrary to a proposed anti-GQ1b antibody syndrome, we would suggest that pathogenesis of this clinical spectrum is not limited to anti-ganglioside antibodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22698187", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1073, "text": "Although there are usually no abnormalities in MFS by routine neuroimaging, in a few cases, contrast enhancement of nerve roots and signs of central nervous system involvement were described supporting the hypothesis of an anti-GQ1b-syndrome, a continuum involving GBS, MFS, and Bickerstaff's brainstem encephalitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21631649", "endSection": "abstract"}, {"offsetInBeginSection": 713, "offsetInEndSection": 785, "text": "Anti-GM1 IgG, GD1a IgG, GQ1b IgG, and GT1a IgG antibodies were positive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275783", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 330, "text": "The discovery of the association of the anti-GQ1b IgG antibody with the postinfectious clinical syndromes of ophthalmoplegia, ataxia, and areflexia helped house the phenotypes of the Miller Fisher syndrome (MFS), atypical MFS, Guillain-Barr\u00e9 syndrome with ophthalmoplegia, and Bickerstaff's brainstem encephalitis under one roof. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19664367", "endSection": "abstract"}]}, {"body": "What is the function of the AtxA pleiotropic regulator?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24661624", "http://www.ncbi.nlm.nih.gov/pubmed/22636778", "http://www.ncbi.nlm.nih.gov/pubmed/20863885", "http://www.ncbi.nlm.nih.gov/pubmed/18676674", "http://www.ncbi.nlm.nih.gov/pubmed/14702298", "http://www.ncbi.nlm.nih.gov/pubmed/9199422", "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "http://www.ncbi.nlm.nih.gov/pubmed/9106214", "http://www.ncbi.nlm.nih.gov/pubmed/9119194", "http://www.ncbi.nlm.nih.gov/pubmed/8577251"], "ideal_answer": ["AtxA is the gene encoding the trans-activator of anthrax toxin synthesis and is essential for virulence of B. anthracis. It is located on the resident 185-kb plasmid pXO1 and its activation is stimulated by bicarbonate. AtxA controls the expression of more than a hundred genes belonging to all genetic elements, the chromosome and both virulence plasmids, including those encoding the major virulence factors. AtxA can activate or repress gene expression. In atxA+ strains, toxin gene expression is increased 5- to 20-fold in cells grown in 5% CO2 relative to cells grown in air. Dual promoters control expression of AtxA.  Transcription of the atxA gene occurs from two independent promoters, P1 and P2, whose transcription start sites are separated by 650 bp.", "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.", "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.", "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.", "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.", "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.", "Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. The AtxA virulence regulator of Bacillus anthracis is required for toxin and capsule gene expression. DNA sequence analysis of transposon insertion sites in 17 mutants carrying CO2- and atxA-regulated fusions revealed 10 mutants carrying independent insertions on the 185-kb toxin plasmid pXO1 which did not map to the toxin genes. We purified histidine-tagged AtxA [AtxA(His)] from Escherichia coli and used anti-AtxA(His) serum to detect AtxA in protein preparations from B. anthracis cells."], "type": "summary", "id": "5710a51bcf1c325851000029", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8577251", "endSection": "title"}, {"offsetInBeginSection": 1281, "offsetInEndSection": 1322, "text": "The atxA-null mutant is avirulent in mice", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8577251", "endSection": "abstract"}, {"offsetInBeginSection": 1446, "offsetInEndSection": 1546, "text": "These data suggest that the atxA gene product also regulates toxin gene expression during infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8577251", "endSection": "abstract"}, {"offsetInBeginSection": 570, "offsetInEndSection": 716, "text": "Thus, we conclude that the pX01 influence on capsule synthesis is mediated by AtxA, the pXO1-encoded trans-activator of the toxin gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9119194", "endSection": "abstract"}, {"offsetInBeginSection": 68, "offsetInEndSection": 138, "text": "atxA, the gene encoding the trans-activator of anthrax toxin synthesis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9106214", "endSection": "title"}, {"offsetInBeginSection": 189, "offsetInEndSection": 385, "text": "The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9106214", "endSection": "abstract"}, {"offsetInBeginSection": 1447, "offsetInEndSection": 1580, "text": " Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9106214", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 342, "text": "In atxA+ strains, toxin gene expression is increased 5- to 20-fold in cells grown in 5% CO2 relative to cells grown in air.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}, {"offsetInBeginSection": 1442, "offsetInEndSection": 1648, "text": "Our data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}, {"offsetInBeginSection": 1623, "offsetInEndSection": 1819, "text": " Our data strongly suggest that an additional factor(s) is involved in regulation of pag and that the relative amounts of such a factor(s) and AtxA are important for optimal toxin gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9199422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Two regulatory genes, acpA and atxA, have been reported to control expression of the Bacillus anthracis capsule biosynthesis operon capBCAD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14702298", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 238, "text": "The atxA gene is located on the virulence plasmid pXO1, while pXO2 carries acpA and the cap genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14702298", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Dual promoters control expression of the Bacillus anthracis virulence factor AtxA.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18676674", "endSection": "title"}, {"offsetInBeginSection": 273, "offsetInEndSection": 554, "text": "Here we report that transcription of the atxA gene occurs from two independent promoters, P1 (previously described by Dai et al. [Z. Dai, J. C. Sirard, M. Mock, and T. M. Koehler, Mol. Microbiol. 16:1171-1181, 1995]) and P2, whose transcription start sites are separated by 650 bp.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18676674", "endSection": "abstract"}, {"offsetInBeginSection": 142, "offsetInEndSection": 379, "text": "AtxA controls the expression of more than a hundred genes belonging to all genetic elements, the chromosome and both virulence plasmids, including those encoding the major virulence factors. AtxA can activate or repress gene expression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20863885", "endSection": "abstract"}, {"offsetInBeginSection": 714, "offsetInEndSection": 1012, "text": "Here we employ 5' and 3' deletion analysis and site-directed mutagenesis of the atxA control region to demonstrate that atxA transcription from the major start site P1 is dependent upon a consensus sequence for the housekeeping sigma factor SigA and an A+T-rich upstream element for RNA polymerase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22636778", "endSection": "abstract"}, {"offsetInBeginSection": 1013, "offsetInEndSection": 1262, "text": "We also show that an additional trans-acting protein(s) binds specifically to atxA promoter sequences located between -13 and +36 relative to P1 and negatively impacts transcription. Deletion of this region increases promoter activity up to 15-fold.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22636778", "endSection": "abstract"}, {"offsetInBeginSection": 1503, "offsetInEndSection": 1786, "text": "A majority of genes on the virulence plasmid pXO1 that are regulated by the presence of either CO2 or AtxA separately are also regulated synergistically in the presence of both. These results also elucidate novel pXO1-encoded small RNAs that are associated with virulence conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661624", "endSection": "abstract"}, {"offsetInBeginSection": 287, "offsetInEndSection": 388, "text": "This response requires the presence of the pXO1 virulence plasmid-encoded pleiotropic regulator AtxA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661624", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661624", "endSection": "title"}, {"offsetInBeginSection": 878, "offsetInEndSection": 1169, "text": "The majority of the regulated genes responded to both AtxA and carbon dioxide rather than to just one of these factors. Interestingly, we identified two previously unrecognized small RNAs that are highly expressed under physiological carbon dioxide concentrations in an AtxA-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661624", "endSection": "abstract"}]}, {"body": "Can cffDNA be used for non-invasive testing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24482806"], "ideal_answer": ["Yes, cell-free fetal DNA (cffDNA) has made non-invasive prenatal testing possible."], "exact_answer": "yes", "type": "yesno", "id": "57135fae1174fb1755000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482806", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "The identification of cell-free fetal DNA (cffDNA) in maternal circulation has made non-invasive prenatal testing (NIPT) possible.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482806", "endSection": "abstract"}, {"offsetInBeginSection": 420, "offsetInEndSection": 1068, "text": "In recent years, technical advances in the molecular analysis of fetal DNA (e.g., digital PCR and massively parallel sequencing (MPS)) has enabled the successful implementation of noninvasive testing into clinical practice, such as fetal sex assessment, RhD genotyping, and fetal chromosomal aneuploidy detection.With the ability to decipher the entire fetal genome from maternal plasma DNA, we foresee that an increased number of non-invasive prenatal tests will be available for detecting many single-gene disorders in the near future. This review briefly summarizes the technical aspects of the NIPT and application of NIPT in clinical practice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482806", "endSection": "abstract"}]}, {"body": "Which is the underlying mechanism for exon skipping used to treat Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24380394", "http://www.ncbi.nlm.nih.gov/pubmed/23521559"], "ideal_answer": ["Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein. Many Duchenne Muscular Dystrophy patients need exon skipping of multiple exons in order to restore the reading frame, depending on how many base pairs the mutated exon(s) and adjacent exons have.", "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein", "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein", "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein", "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein", "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein", "Antisense oligonucleotides (AONs) that bind to complementary sequences of the dystrophin pre-mRNA to induce skipping of the targeted exon by modulating pre-mRNA splicing are promising therapeutic agents for DMD. In addition, multiple exon skipping could be used to select deletions that optimize the functionality of the truncated dystrophin protein. Theoretically, multiple exon skipping could be used to treat approximately 90%, 80%, and 98% of DMD patients with deletion, duplication, and nonsense mutations, respectively. One major challenge has been its limited applicability.", "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein "], "type": "summary", "id": "5713394af9287de436000001", "snippets": [{"offsetInBeginSection": 201, "offsetInEndSection": 462, "text": "Antisense-mediated exon skipping therapy is a promising therapeutic approach that uses short DNA-like molecules called antisense oligonucleotides (AOs) to skip over/splice out the mutated part of the gene to produce a shortened but functional dystrophin protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24380394", "endSection": "abstract"}, {"offsetInBeginSection": 597, "offsetInEndSection": 942, "text": "many DMD patients need exon skipping of multiple exons in order to restore the reading frame, depending on how many base pairs the mutated exon(s) and adjacent exons have. Theoretically, multiple exon skipping could be used to treat approximately 90%, 80%, and 98% of DMD patients with deletion, duplication, and nonsense mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24380394", "endSection": "abstract"}, {"offsetInBeginSection": 283, "offsetInEndSection": 659, "text": "Antisense oligonucleotides (AONs) that bind to complementary sequences of the dystrophin pre-mRNA to induce skipping of the targeted exon by modulating pre-mRNA splicing are promising therapeutic agents for DMD. Such AONs can restore the open reading frame of the DMD gene and produce internally deleted, yet partially functional dystrophin protein isoforms in skeletal muscle", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23521559", "endSection": "abstract"}]}, {"body": "Are pseudogenes enriched with housekeeping protein families?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18957444"], "ideal_answer": ["Yes, housekeeping families tend to be enriched with a large number of pseudogenes."], "exact_answer": "yes", "type": "yesno", "id": "5709f212cf1c325851000020", "snippets": [{"offsetInBeginSection": 1370, "offsetInEndSection": 1446, "text": "housekeeping families tend to be enriched with a large number of pseudogenes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957444", "endSection": "abstract"}]}, {"body": "Mutation of which gene is implicated in the Brain-lung-thyroid syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26196025", "http://www.ncbi.nlm.nih.gov/pubmed/25759798", "http://www.ncbi.nlm.nih.gov/pubmed/24129101", "http://www.ncbi.nlm.nih.gov/pubmed/24171694", "http://www.ncbi.nlm.nih.gov/pubmed/22488412", "http://www.ncbi.nlm.nih.gov/pubmed/22166853", "http://www.ncbi.nlm.nih.gov/pubmed/21867529"], "ideal_answer": ["Brain-lung-thyroid syndrome (BLTS) characterized by congenital hypothyroidism, respiratory distress syndrome, and benign hereditary chorea is caused by thyroid transcription factor 1 (NKX2-1/TTF1) mutations."], "exact_answer": [["thyroid transcription factor 1"]], "type": "factoid", "id": "56c1f03bef6e394741000053", "snippets": [{"offsetInBeginSection": 151, "offsetInEndSection": 362, "text": " The disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the \"brain-lung-thyroid syndrome\", in which additional developmental abnormalities of lung and thyroid tissue are observed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26196025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Novel NKX2-1 Frameshift Mutations in Patients with Atypical Phenotypes of the Brain-Lung-Thyroid Syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759798", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "OBJECTIVES: To verify the involvement of NKX2-1 gene in infants with brain-lung-thyroid (BLT) syndrome and hypothyroid phenotypes variable among congenital hypothyroidism (CH) or idiopathic mild hypothyroidism (IMH) of postnatal onset.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759798", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 988, "text": "They were carriers of new de novo heterozygous frameshift mutations of NKX2-1 (c.177delG and c.153_166del14).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759798", "endSection": "abstract"}, {"offsetInBeginSection": 1273, "offsetInEndSection": 1444, "text": "CONCLUSIONS: Two novel heterozygous frameshift mutations of NKX2-1 were identified in 2 cases selected on the basis of a BLT-like phenotype among 183 hypothyroid infants. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759798", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "NKX2-1 mutations in brain-lung-thyroid syndrome: a case series of four patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129101", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Brain-lung-thyroid syndrome (BLTS) characterized by congenital hypothyroidism, respiratory distress syndrome, and benign hereditary chorea is caused by thyroid transcription factor 1 (NKX2-1/TTF1) mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129101", "endSection": "abstract"}, {"offsetInBeginSection": 364, "offsetInEndSection": 1250, "text": "Two of the four patients presenting with the triad of BLTS had NKX2-1 mutations, and one of these NKX2-1 [c.890_896del (p.Ala327Glyfs*52)] is a novel variant. The third patient without any identified NKX2-1 mutations was a carrier of mitochondrial mutation; this raises the possibility of mitochondrial mutations contributing to thyroid dysgenesis. Although rare, the triad of congenital hypothyroidism, neurological, and respiratory signs is highly suggestive of NKX2-1 anomalies. Screening for NKX2-1 mutations in patients with thyroid, lung, and neurological abnormalities will enable a unifying diagnosis and genetic counseling for the affected families. In addition, identification of an NKX2-1 defect would be helpful in allaying the concerns about inadequate thyroxine supplementation as the cause of neurological defects observed in some children with congenital hypothyroidism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129101", "endSection": "abstract"}, {"offsetInBeginSection": 205, "offsetInEndSection": 377, "text": "Loss-of-function mutations in NKX2.1, a gene vital to the normal development and function of the brain, lungs, and thyroid, have been identified in a number of individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171694", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "BACKGROUND: NKX2.1 mutations have been identified in patients displaying complete or partial brain-lung-thyroid syndrome, which can include benign hereditary chorea (BHC), hypothyroidism and/or lung disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488412", "endSection": "abstract"}, {"offsetInBeginSection": 873, "offsetInEndSection": 1057, "text": "CONCLUSION: MLPA should be considered as a complementary tool in patients with partial or total brain-lung-thyroid syndrome when direct sequencing failed to identify NKX2.1 mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488412", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Mutations in NKX2-1 cause neurological, pulmonary, and thyroid hormone impairment. Recently, the disease was named brain-lung-thyroid syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22166853", "endSection": "abstract"}, {"offsetInBeginSection": 384, "offsetInEndSection": 808, "text": "Genetic analysis of NKX2-1 revealed a novel missense mutation (p.Val205Phe) in two patients who were cousins and their maternal families, and a novel 2.6-Mb deletion including NKX2-1 on chromosome 14 in the other patient. Congenital hypothyroidism was not detected on neonatal screening in the patient with the missense mutation, and frequent respiratory infections were observed in the patient with the deletion in NKX2-1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22166853", "endSection": "abstract"}, {"offsetInBeginSection": 152, "offsetInEndSection": 420, "text": "Haploinsufficiency of NKX2.1, the gene encoding the thyroid transcription factor-1 (TTF-1)--critical for lung, thyroid and central nervous system morphogenesis and function--causes a rare form of progressive respiratory failure designated brain-lung-thyroid syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21867529", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 607, "text": "We report a novel TTF-1 molecular defect causing recurrent respiratory failure episodes in an infant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21867529", "endSection": "abstract"}]}, {"body": "Which metabolite activates AtxA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17302798", "http://www.ncbi.nlm.nih.gov/pubmed/24661624", "http://www.ncbi.nlm.nih.gov/pubmed/21923765", "http://www.ncbi.nlm.nih.gov/pubmed/15149039", "http://www.ncbi.nlm.nih.gov/pubmed/9199422", "http://www.ncbi.nlm.nih.gov/pubmed/9234759"], "ideal_answer": ["Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. Cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state. CO2-enhanced toxin gene transcription is not observed in atx4-null mutants. Overall data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins.", "Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. The Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C. A corresponding difference in AtxA protein was also seen at the different growth temperatures. All mutants multimerized, but one mutation, C402S, prevented cross-linking."], "exact_answer": [["CO2", "bicarbonate"]], "type": "factoid", "id": "5710a592cf1c32585100002a", "snippets": [{"offsetInBeginSection": 217, "offsetInEndSection": 471, "text": "Here we report that bioinformatic analyses suggested the presence in AtxA of two PTS (phosphenolpyruvate : sugar phosphotransferase system) regulation domains (PRD) generally regulated by phosphorylation/dephosphorylation at conserved histidine residues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17302798", "endSection": "abstract"}, {"offsetInBeginSection": 1161, "offsetInEndSection": 1342, "text": "Our results link virulence factor production in B. anthracis to carbohydrate metabolism and, for the first time, provide a mechanistic explanation for AtxA transcriptional activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17302798", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 286, "text": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24661624", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 330, "text": "The 475 amino acid sequence of AtxA reveals DNA binding motifs and regions similar to proteins associated with the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21923765", "endSection": "abstract"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1577, "text": "cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21923765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal mimicking the host environment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149039", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 941, "text": "Furthermore, in vitro in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9199422", "endSection": "title"}, {"offsetInBeginSection": 165, "offsetInEndSection": 332, "text": " In atxA+ strains, expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate and temperature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9199422", "endSection": "abstract"}, {"offsetInBeginSection": 841, "offsetInEndSection": 1130, "text": "Our data indicate that atxA expression is not influenced by CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9199422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "The Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 418, "text": "CO2-enhanced toxin gene transcription is not observed in atx4-null mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 837, "text": "Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1293, "text": "Transposon-insertion libraries were screened for mutants expressing CO2-enhanced atxA-dependent beta-galactosidase activity. DNA sequence analysis of transposon insertion sites in 17 mutants carrying CO2- and atxA-regulated fusions revealed 10 mutants carrying independent insertions on the 185-kb toxin plasmid pXO1 which did not map to the toxin genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}, {"offsetInBeginSection": 1446, "offsetInEndSection": 1648, "text": "data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9234759", "endSection": "abstract"}]}, {"body": "How can the fetal Rhesus be determined with non-invasive testing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24778561", "http://www.ncbi.nlm.nih.gov/pubmed/26152007"], "ideal_answer": ["The detection of fetal RhD status can be achieved with the non-invasive method of assessing free fetal DNA in the maternal blood."], "exact_answer": [["free fetal DNA from maternal cirulcation"]], "type": "factoid", "id": "571366ba1174fb1755000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Determination of fetal rhesus d status by maternal plasma DNA analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "In this study, we assessed the feasibility of fetal RhD genotyping by analysis of cell-free fetal DNA(cffDNA) extracted from plasma samples of Rhesus (Rh) D-negative pregnant women by using real-time polymerase chain reaction (PCR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "endSection": "abstract"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1172, "text": "Performing real-time PCR on cffDNA showed accurate, efficient and reliable results, allowing rapid and high throughput non invasive determination of fetal sex and RhD status in clinical samples", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778561", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Non-invasive prenatal diagnosis of fetal RhD by using free fetal DNA", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "endSection": "title"}, {"offsetInBeginSection": 138, "offsetInEndSection": 311, "text": "The aim of this study is to determine fetal RhD status in the Rh incompatible pregnancies with an non-invasive technique; free fetal DNA isolation from maternal circulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "endSection": "abstract"}, {"offsetInBeginSection": 1057, "offsetInEndSection": 1405, "text": " The detection of fetal RhD status by using a non-invasive method from maternal circulation was found to be possible. Assessing fetal RhD status non-invasively by using free fetal DNA in maternal blood will be cost-efficient, avoiding unnecessary indirect Coombs test and unnecessary Rhogam applications that is used in RH incompatible pregnancies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152007", "endSection": "abstract"}]}, {"body": "Is muscle regeneration possible in mdx mice with the use of induced mesenchymal stem cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25102299"], "ideal_answer": ["Purified induced mesenchymal stem cells (iMSCs) display fibroblast-like morphology, form three-dimensional spheroid structures, express characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105, and are capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplantation of iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowers oxidative damage, and restores the expression levels of normal dystrophin, leading to skeletal muscle regeneration.", "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored", "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored", "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored", "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored", "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored"], "exact_answer": "yes", "type": "yesno", "id": "57134d511174fb1755000002", "snippets": [{"offsetInBeginSection": 622, "offsetInEndSection": 1147, "text": "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299", "endSection": "abstract"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1260, "text": "This study demonstrates the therapeutic potential of purified iMSCs in skeletal muscle regeneration in mdx mice", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Flk-1+ adipose-derived mesenchymal stem cells differentiate into skeletal muscle satellite cells and ameliorate muscular dystrophy in mdx mice", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999592", "endSection": "title"}, {"offsetInBeginSection": 531, "offsetInEndSection": 784, "text": "Within mdx mice, an animal model of DMD, adipose tissue-derived Flk-1(+) MSCs (AD-MSCs) homed to and differentiated into cells that repaired injured muscle tissue. This repair correlated with reconstitution of dystrophin expression on the damaged fibers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999592", "endSection": "abstract"}, {"offsetInBeginSection": 1076, "offsetInEndSection": 1133, "text": "Flk-1(+) AD-MSC transplants may repair muscular dystrophy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999592", "endSection": "abstract"}]}, {"body": "Can the apoptosis regulator BAX trigger the release of cytochrome c?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25619640", "http://www.ncbi.nlm.nih.gov/pubmed/25524600", "http://www.ncbi.nlm.nih.gov/pubmed/25116390", "http://www.ncbi.nlm.nih.gov/pubmed/23954445", "http://www.ncbi.nlm.nih.gov/pubmed/23567751", "http://www.ncbi.nlm.nih.gov/pubmed/22116711", "http://www.ncbi.nlm.nih.gov/pubmed/21307199"], "ideal_answer": ["Yes, altered Bax conformation trigger its redistribution from the cytosol to mitochondria. Subsequently, cytochrome c is released from mitochondria to cytosol."], "exact_answer": "yes", "type": "yesno", "id": "5717bacacb4ef8864c00000d", "snippets": [{"offsetInBeginSection": 548, "offsetInEndSection": 684, "text": "6-Shogaol reduced the mitochondrial membrane potential (MMP) and released cytochrome c from mitochondria to cytosol via Bax activation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25619640", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 676, "text": "Moreover, overexpression of ER\u03b2 prevented Bax activation, cytochrome c release, caspase-3 activation, and PARP cleavage during apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25524600", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 573, "text": "In this study, we demonstrated that EV71 infection altered Bax conformation and triggered its redistribution from the cytosol to mitochondria in RD cells. Subsequently, cytochrome c was released from mitochondria to cytosol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116390", "endSection": "abstract"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1218, "text": "associated with translocation of Bax from the cytosol to the mitochondrial membrane, cytochrome c release, and caspase activation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954445", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 397, "text": "Once activated, BAK and BAX form proteolipid pores in the OMM leading to mitochondrial outer membrane permeabilization (MOMP), and the release of inner membrane space proteins, such as cytochrome c, which promotes caspase activation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567751", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 809, "text": " Our results showed that OC induced a caspase-dependent apoptosis by triggering a series of events in HeLa cells including Bax translocation, cytochrome c release, caspase-3 activation, chromosome fragmentation followed by caspase-8 activation, Bid cleavage and eventually cell death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22116711", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 411, "text": "Bax plays a key role in intrinsic apoptotic signaling in neurons by allowing the release of mitochondrial cytochrome c. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21307199", "endSection": "abstract"}]}, {"body": "Does TRIM37 gene mutation causes Mulibrey nanism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21865362", "http://www.ncbi.nlm.nih.gov/pubmed/19334051", "http://www.ncbi.nlm.nih.gov/pubmed/19329943"], "ideal_answer": ["Yes, Mulibrey nanism is caused by recessive mutations in the TRIM37 gene encoding for the peroxisomal TRIM37 protein with ubiquitin-ligase activity."], "exact_answer": "yes", "type": "yesno", "id": "56c1f03cef6e394741000054", "snippets": [{"offsetInBeginSection": 93, "offsetInEndSection": 225, "text": "OBJECTIVE: We studied pubertal development and fecundity in males with Mulibrey nanism (MUL) caused by mutations in the TRIM37 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21865362", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1714, "text": "In MUL, mutations in TRIM37 lead to disturbance of sexual maturation, and fertility is severely compromised. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21865362", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 298, "text": "It is caused by recessive mutations in the TRIM37 gene encoding for the peroxisomal TRIM37 protein with ubiquitin-ligase activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19334051", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Mulibrey nanism is an autosomal recessive growth disorder caused by mutations in the TRIM37 gene encoding a protein of unknown function. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19329943", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19329943", "endSection": "title"}, {"offsetInBeginSection": 602, "offsetInEndSection": 864, "text": "To investigate the possible involvement of TRIM37 alterations in the pathogenesis of sporadic fibrothecomas, we analyzed the TRIM37 cDNA for mutations and alternatively spliced transcripts and TRIM37 expression in fibrothecomas of women without Mulibrey nanism. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19329943", "endSection": "abstract"}, {"offsetInBeginSection": 1684, "offsetInEndSection": 1918, "text": " In conclusion, inherited biallelic inactivation of TRIM37 (Mulibrey nanism) predisposes to both mesenchymal and epithelial ovarian tumors and dysregulation of TRIM37 may also be involved in the pathogenesis of sporadic fibrothecomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19329943", "endSection": "abstract"}]}, {"body": "Is Mycobacterium avium less susceptible to antibiotics than Mycobacterium tuberculosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21258569", "http://www.ncbi.nlm.nih.gov/pubmed/19302308", "http://www.ncbi.nlm.nih.gov/pubmed/16410940", "http://www.ncbi.nlm.nih.gov/pubmed/15347635", "http://www.ncbi.nlm.nih.gov/pubmed/12355367", "http://www.ncbi.nlm.nih.gov/pubmed/10988097", "http://www.ncbi.nlm.nih.gov/pubmed/1441463", "http://www.ncbi.nlm.nih.gov/pubmed/19956964"], "ideal_answer": ["Mycobacterium avium causes disseminated infection in patients with acquired immune deficiency syndrome. M tuberculosis disease is preventable and curable and yet communicable, physicians should maintain a high degree of suspicion for tuberculosis in HIV-infected adults. In comparison, the goal of treating M avium complex in patients with advanced HIV disease is to reduce constitutional symptoms and improve survival. Patients who were suspected to have disseminated mycobacterial infection, presenting fever and (preferably) a CD4 T cell count<100.0 cell/mL were investigated. Twelve (15%) of the 80 blood cultures were positive for mycobacteria, with Mycobacterium avium being identified in 7 (8.8%) samples and M. tuberculosis in 5 (6.2%).  The antimycobacterial activities of RS-112997, RS-124922 and RS-118641, three capuramycin analogues that inhibit phospho-N-acetylmuramyl-pentapeptide translocase, were tested against clinical isolates of Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare. The MIC50/90 (mg/L) results for RS-118641 were: M. tuberculosis, 1/2; multidrug-resistant (MDR) M. tuberculosis, 0.5/2; M. avium, 4/8; and M. intracellulare, 0.06/0.5"], "exact_answer": "yes", "type": "yesno", "id": "5710a650cf1c32585100002b", "snippets": [{"offsetInBeginSection": 1447, "offsetInEndSection": 1550, "text": "The prevalence of MAC lung infection in two inner city hospitals was four times higher than that of TB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21258569", "endSection": "abstract"}, {"offsetInBeginSection": 1792, "offsetInEndSection": 1908, "text": "Most patients with combined infection were clinically consistent with MTB and responded to anti MTB treatment alone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21258569", "endSection": "abstract"}, {"offsetInBeginSection": 1719, "offsetInEndSection": 1868, "text": "The triplex PCR developed by us could be used to detect and differentiate M. tuberculosis, M. avium and other mycobacteria in a single reaction tube.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19302308", "endSection": "abstract"}, {"offsetInBeginSection": 402, "offsetInEndSection": 567, "text": "Twelve (15%) of the 80 blood cultures were positive for mycobacteria, with Mycobacterium avium being identified in 7 (8.8%) samples and M. tuberculosis in 5 (6.2%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16410940", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 296, "text": "The antimycobacterial activities of RS-112997, RS-124922 and RS-118641, three capuramycin analogues that inhibit phospho-N-acetylmuramyl-pentapeptide translocase, were tested against clinical isolates of Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347635", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 627, "text": "The MIC50/90 (mg/L) results for RS-118641 were: M. tuberculosis, 1/2; multidrug-resistant (MDR) M. tuberculosis, 0.5/2; M. avium, 4/8; and M. intracellulare, 0.06/0.5", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347635", "endSection": "abstract"}, {"offsetInBeginSection": 1456, "offsetInEndSection": 1692, "text": "These results suggest that capuramycin analogues exhibit strong antimycobacterial potential and should be considered for further evaluation in the treatment of M. tuberculosis and M. avium-M. intracellulare complex infections in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15347635", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Mycobacterium avium causes disseminated infection in patients with acquired immune deficiency syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12355367", "endSection": "abstract"}, {"offsetInBeginSection": 421, "offsetInEndSection": 694, "text": "Overall incidences of Mycobacterium tuberculosis (TB) and Mycobacterium avium complex (MAC) were 0.8 and 1.4 cases/100 person-years of follow-up (PYF), decreasing from 1.8 (TB) and 3.5 cases/100 PYF (MAC) before September 1995 to 0.3 and 0.2 cases/100 PYF after March 1997.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10988097", "endSection": "abstract"}, {"offsetInBeginSection": 427, "offsetInEndSection": 750, "text": "Because M tuberculosis disease is preventable and curable and yet communicable, physicians should maintain a high degree of suspicion for tuberculosis in HIV-infected adults. In comparison, the goal of treating M avium complex in patients with advanced HIV disease is to reduce constitutional symptoms and improve survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1441463", "endSection": "abstract"}, {"offsetInBeginSection": 1210, "offsetInEndSection": 1385, "text": "MAC pulmonary disease should be considered in the differential diagnosis of SPNs, even when encountered in geographic regions with a high prevalence of pulmonary tuberculosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19956964", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 400, "text": "From April 2001 to February 2002, 80 blood samples from patients who were suspected to have disseminated mycobacterial infection, presenting fever and (preferably) a CD4 T cell count<100.0 cell/mL were investigated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16410940", "endSection": "abstract"}]}, {"body": "How early during pregnancy does non-invasive cffDNA testing allow sex determination of the fetus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25343090", "http://www.ncbi.nlm.nih.gov/pubmed/23690098"], "ideal_answer": ["Using cffDNA from maternal blood, the fetal gender can be determined as early as 6 to 10 weeks of gestation (during the first trimester of pregnancy)."], "exact_answer": [["6th to 10th week of gestation", "first trimester of pregnancy"]], "type": "factoid", "id": "57136a7e1174fb1755000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "The use of cffDNA in fetal sex determination during the first trimester of pregnancy of female DMD carriers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25343090", "endSection": "title"}, {"offsetInBeginSection": 403, "offsetInEndSection": 561, "text": "We determined fetal sex during the first trimester using a quantitative real-time polymerase chain reaction (PCR) assay of cffDNA in pregnant carriers of DMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25343090", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Early fetal gender determination using real-time PCR analysis of cell-free fetal DNA during 6th-10th weeks of gestation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23690098", "endSection": "title"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1391, "text": "Considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester of pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23690098", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 1001, "text": "Therefore in this study, the probability of detecting sequences on the human Y-chromosome in pregnant women has been evaluated to identify the gender of fetuses. Peripheral blood samples were obtained from 80 pregnant women with gestational age between 6th to 10th weeks and the fetal DNA was extracted from the plasma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23690098", "endSection": "abstract"}]}, {"body": "What is the effect of amitriptyline in the mdx mouse model of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24972834"], "ideal_answer": ["Amitriptyline treatment had anxiolytic and antidepressant effects in mdx mice associated with elevations in serotonin levels in the amygdala and hippocampus. On the other hand, inflammation in mdx skeletal muscle tissue was also reduced as indicated by decreased immune cell infiltration of muscle and lower levels of the pro-inflammatory cytokines tumour necrosis factor-\u03b1 and interleukin-6 in the forelimb flexors.", "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy", "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy", "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy", "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy", "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy", "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy "], "type": "summary", "id": "5713506d1174fb1755000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24972834", "endSection": "title"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1252, "text": "Amitriptyline treatment had anxiolytic and antidepressant effects in mdx mice associated with elevations in serotonin levels in the amygdala and hippocampus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24972834", "endSection": "abstract"}, {"offsetInBeginSection": 1253, "offsetInEndSection": 1643, "text": " Inflammation in mdx skeletal muscle tissue was also reduced following amitriptyline treatment as indicated by decreased immune cell infiltration of muscle and lower levels of the pro-inflammatory cytokines tumour necrosis factor-\u03b1 and interleukin-6 in the forelimb flexors. Interleukin-6 mRNA expression was remarkably reduced in the amygdala of mdx mice by chronic amitriptyline treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24972834", "endSection": "abstract"}]}, {"body": "List inhibtors targeting the mitochondrial permeability transition pore.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25793558", "http://www.ncbi.nlm.nih.gov/pubmed/24657357", "http://www.ncbi.nlm.nih.gov/pubmed/25351957", "http://www.ncbi.nlm.nih.gov/pubmed/24675465", "http://www.ncbi.nlm.nih.gov/pubmed/24968303", "http://www.ncbi.nlm.nih.gov/pubmed/24615518", "http://www.ncbi.nlm.nih.gov/pubmed/25502879", "http://www.ncbi.nlm.nih.gov/pubmed/24801220", "http://www.ncbi.nlm.nih.gov/pubmed/24627421", "http://www.ncbi.nlm.nih.gov/pubmed/24273204", "http://www.ncbi.nlm.nih.gov/pubmed/24885907", "http://www.ncbi.nlm.nih.gov/pubmed/23423267", "http://www.ncbi.nlm.nih.gov/pubmed/23536162", "http://www.ncbi.nlm.nih.gov/pubmed/24349464", "http://www.ncbi.nlm.nih.gov/pubmed/22197697", "http://www.ncbi.nlm.nih.gov/pubmed/22198507", "http://www.ncbi.nlm.nih.gov/pubmed/22745676", "http://www.ncbi.nlm.nih.gov/pubmed/20966765", "http://www.ncbi.nlm.nih.gov/pubmed/21542787", "http://www.ncbi.nlm.nih.gov/pubmed/21294074", "http://www.ncbi.nlm.nih.gov/pubmed/21372381", "http://www.ncbi.nlm.nih.gov/pubmed/20937730", "http://www.ncbi.nlm.nih.gov/pubmed/21669242", "http://www.ncbi.nlm.nih.gov/pubmed/20960209", "http://www.ncbi.nlm.nih.gov/pubmed/20668412", "http://www.ncbi.nlm.nih.gov/pubmed/19819119"], "ideal_answer": ["Cyclosporine A\nAtractyloside\nN-metyl-4-isoleucine-cyclosporine\nSanglifehrin A \nTRO-19622", "The opening of the mitochondrial permeability transition pore appears to be inhibited by KB-R 7943, diacylglycerol analog 1-oleoyl-2-acetyl-sn-glycerol, cyclosporin A (CsA) and BRL37344."], "exact_answer": [["Cyclosporine A"], ["Atractyloside"], ["N-metyl-4-isoleucine-cyclosporine", "NIM811"], ["Sanglifehrin A"], ["TRO-19622"]], "type": "list", "id": "5717cdd2070aa3d072000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Postconditioning with cyclosporine a reduces early renal dysfunction by inhibiting mitochondrial permeability transition.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793558", "endSection": "title"}, {"offsetInBeginSection": 767, "offsetInEndSection": 837, "text": "mitochondrial permeability transition pore inhibitor (Cyclosporine A).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24657357", "endSection": "abstract"}, {"offsetInBeginSection": 1235, "offsetInEndSection": 1283, "text": " treatment with the MPTP inhibitor atractyloside", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351957", "endSection": "abstract"}, {"offsetInBeginSection": 1242, "offsetInEndSection": 1277, "text": " cyclosporine A, an MPTP inhibitor,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675465", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 382, "text": "NIM-811 (N-metyl-4-isoleucine-cyclosporine) is a mitochondria specific drug, which can prevent ischemic-reperfusion (IR) injury, by inhibiting mitochondrial permeability transition pores (mPTP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24968303", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 580, "text": " The mPTP inhibitor sanglifehrin A (SfA) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24615518", "endSection": "abstract"}, {"offsetInBeginSection": 1618, "offsetInEndSection": 1654, "text": "mPTP inhibitor, cyclosporin A (CsA),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25502879", "endSection": "abstract"}, {"offsetInBeginSection": 668, "offsetInEndSection": 708, "text": "cyclosporine A (CsA), a MPTP inhibitor, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24801220", "endSection": "abstract"}, {"offsetInBeginSection": 710, "offsetInEndSection": 736, "text": "The mPTP inhibitor NIM811,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627421", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 767, "text": "A mPTP inhibitor (TRO-19622)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24273204", "endSection": "abstract"}, {"offsetInBeginSection": 954, "offsetInEndSection": 1038, "text": "Cyclosporine A (CsA), a mitochondria permeability transition pore (MPTP) inhibitor, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885907", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 668, "text": " and N-methyl-4-isoleucine cyclosporine (NIM811), an mPTP inhibitor, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23423267", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 539, "text": "mPTP inhibitor cyclosporin A (CsA) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "ADP is not only a key substrate for ATP generation, but also a potent inhibitor of mitochondrial permeability transition pore (mPTP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349464", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 734, "text": "MPTP inhibitor cyclosporin A", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22197697", "endSection": "abstract"}, {"offsetInBeginSection": 1476, "offsetInEndSection": 1506, "text": " mPTP inhibitor cyclosporin A ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22198507", "endSection": "abstract"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1160, "text": "MPTP inhibitor cyclosporine A (CsA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960209", "endSection": "abstract"}, {"offsetInBeginSection": 1124, "offsetInEndSection": 1158, "text": " the mPTP inhibitor cyclosporine A", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20668412", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 780, "text": "The mPTP inhibitor cyclosporine A (CsA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819119", "endSection": "abstract"}]}, {"body": "Which antibodies cause Riedel thyroiditis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26273473", "http://www.ncbi.nlm.nih.gov/pubmed/25011997", "http://www.ncbi.nlm.nih.gov/pubmed/25224542", "http://www.ncbi.nlm.nih.gov/pubmed/24783026", "http://www.ncbi.nlm.nih.gov/pubmed/22498583", "http://www.ncbi.nlm.nih.gov/pubmed/22210556", "http://www.ncbi.nlm.nih.gov/pubmed/21881964"], "ideal_answer": ["Riedel thyroiditis (Immunoglobulin G4-related thyroid disease) is caused by IgG4 antibodies. It is part of the spectrum of Ig4-related sclerosing disease.\nIt is associated with fibrosis and inflammation of the thyroid gland."], "exact_answer": [["IgG4"]], "type": "factoid", "id": "56c1f040ef6e394741000055", "snippets": [{"offsetInBeginSection": 934, "offsetInEndSection": 1080, "text": "LEARNING POINTS: There are potential clinical applications of identifying subsets of patients with IgG4 thyroiditis (FVHT and Riedel thyroiditis).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26273473", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "The importance of IgG4 in the predictive model of thyroiditis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26273473", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25011997", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "The present study describes in depth a case of Riedel thyroiditis (RT) to clarify its pathogenesis and its putative inclusion in the spectrum of IgG4-related disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25011997", "endSection": "abstract"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1378, "text": "Our findings support the inclusion of RT within the spectrum of IgG4-related thyroid disease (IgG4-RTD). Although the etiology and physiopathology of IgG4-RTD still remain elusive, the results obtained in the present case suggest the participation of lymphatic vessels in the pathogenesis of RT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25011997", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 734, "text": "More than 80 % of the left thyroid lobe was effaced by fibrosis and inflammation (lymphocytes, 57 IgG4+ plasma cells per 1 high-power field, an IgG4/IgG ratio of 0.67, and eosinophils) with extension into the surrounding tissues and occlusive phlebitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25011997", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 624, "text": "Diagnosed early as Riedel disease, the high serum IgG4, immunohistopathology and decreased fibrosis with corticosteroid therapy, finally confirm for the first time, the origin of IgG4-RSD fibrosis of the thyroid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25224542", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 298, "text": " While IgG4-RSD is well documented in the pancreas and other organs, it is poorly characterized in the thyroid gland. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25224542", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 357, "text": "He was careful to distinguish this from Riedel thyroiditis but it has become clear that fibrosis and atrophy of the thyroid are indeed components of Hashimoto thyroiditis, and in rare cases IgG4-related sclerosing disease may be an outcome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24783026", "endSection": "abstract"}, {"offsetInBeginSection": 792, "offsetInEndSection": 978, "text": "The relationship between HT and Riedel thyroiditis remains unclear; however, recent evidence seems to suggest that it may also be part of the spectrum of Ig4-related sclerosing disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22498583", "endSection": "abstract"}, {"offsetInBeginSection": 1295, "offsetInEndSection": 1534, "text": " One patient with advanced thyroid fibrosis associated with Riedel thyroiditis and a history of disease in multiple other organ systems did not have improvement in the thyroid gland, but the disease did not progress to involve new organs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22210556", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 531, "text": "IgG4RD may be present in a certain proportion of patients with a wide variety of diseases, including Mikulicz's disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudotumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881964", "endSection": "abstract"}]}, {"body": "What is the suggested therapy for Mycobacterium avium infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16584300", "http://www.ncbi.nlm.nih.gov/pubmed/9875582", "http://www.ncbi.nlm.nih.gov/pubmed/1387133"], "ideal_answer": ["The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection. TLC G-65 in combination with rifapentine appears to be an attractive regimen for the treatment of infections caused by bacteria in the M. avium complex. Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks. In vivo phage treatment may also be used in some cases.", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection"], "exact_answer": [["Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks"]], "type": "factoid", "id": "5710ade4cf1c32585100002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1387133", "endSection": "abstract"}, {"offsetInBeginSection": 728, "offsetInEndSection": 880, "text": "TLC G-65 in combination with rifapentine appears to be an attractive regimen for the treatment of infections caused by bacteria in the M. avium complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1387133", "endSection": "abstract"}, {"offsetInBeginSection": 379, "offsetInEndSection": 621, "text": "Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9875582", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 493, "text": "TM4 is a lytic mycobacteriophage that kills both extracellular M. avium and M. tuberculosis. When delivered by M. smegmatis transiently infected with TM4, it kills both M. avium and M. tuberculosis within RAW 264.7 macrophages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16584300", "endSection": "abstract"}]}, {"body": "Can fetal aneuploidy be detected with non-invasive prenatal testing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23526649", "http://www.ncbi.nlm.nih.gov/pubmed/25543032"], "ideal_answer": ["Yes, the non-invasive preanatal test of cell-free fetal DNA is being used for fetal aneuploidy screening."], "exact_answer": "yes", "type": "yesno", "id": "57136cbf1174fb1755000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Non-invasive prenatal testing with cell-free DNA: US physician attitudes toward implementation in clinical practice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23526649", "endSection": "title"}, {"offsetInBeginSection": 11, "offsetInEndSection": 200, "text": "The aim of this study was to assess awareness, potential adoption, and current utilization of non-invasive prenatal testing (NIPT) analysis for common fetal aneuploidies among obstetricians", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23526649", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Cell-free DNA has been used for fetal rhesus factor and sex determination, fetal aneuploidy screening, cancer diagnostics and monitoring, and other applications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25543032", "endSection": "abstract"}]}, {"body": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24272589", "http://www.ncbi.nlm.nih.gov/pubmed/23617879", "http://www.ncbi.nlm.nih.gov/pubmed/24293103"], "ideal_answer": ["Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3).", "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem", "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem", "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem", "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem", "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem"], "exact_answer": [["Ataxin-3"]], "type": "factoid", "id": "57138eb21174fb175500000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 321, "text": "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272589", "endSection": "abstract"}, {"offsetInBeginSection": 6, "offsetInEndSection": 164, "text": "Spinocerebellar ataxia type 3 (SCA3) is an inherited spinocerebellar ataxia caused by the expansion of trinucleotide CAG repeats in the gene encoding ataxin-3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23617879", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 368, "text": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293103", "endSection": "abstract"}]}, {"body": "Which is the cellular localization of the protein Opa1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24632637", "http://www.ncbi.nlm.nih.gov/pubmed/23663851", "http://www.ncbi.nlm.nih.gov/pubmed/21459773", "http://www.ncbi.nlm.nih.gov/pubmed/20079867", "http://www.ncbi.nlm.nih.gov/pubmed/12504110", "http://www.ncbi.nlm.nih.gov/pubmed/11847212"], "ideal_answer": ["Opa1 is found normally in the mitochondrial intermembrane space.", "The Opa1 protein localizes to the mitochondria."], "exact_answer": [["mitochondrial intermembrane space"]], "type": "factoid", "id": "5717d64f29809bbe7a000001", "snippets": [{"offsetInBeginSection": 302, "offsetInEndSection": 457, "text": ". The subcellular distribution of mOPA1 overexpressed in COS-7 cells largely overlapped that of endogenous cytochrome c, a well known mitochondrial marker,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11847212", "endSection": "abstract"}, {"offsetInBeginSection": 921, "offsetInEndSection": 990, "text": "elease of high MW Opa-1 isoforms from the mitochondria to the cytosol", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24632637", "endSection": "abstract"}, {"offsetInBeginSection": 832, "offsetInEndSection": 861, "text": " mitochondrial fusion (opa-1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663851", "endSection": "abstract"}, {"offsetInBeginSection": 947, "offsetInEndSection": 1037, "text": "mitochondrial fusion genes Mfn1 (mitofusin 1), Mfn2 (mitofusin 2), Opa1 (optic atrophy 1) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21459773", "endSection": "abstract"}, {"offsetInBeginSection": 488, "offsetInEndSection": 833, "text": "Biochemical examinations indicate that both of the OPA1 isoforms are present in the intermembrane space. Submitochondrial fractionation by sucrose density-gradient centrifugation shows that the 88-kDa protein predominantly associates with the mitochondrial outer membrane, on the contrary, the 93-kDa protein associates with the inner membrane. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12504110", "endSection": "abstract"}]}, {"body": "Is there an association between FGFR3 mutation and plagiocephaly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23949953", "http://www.ncbi.nlm.nih.gov/pubmed/21739570", "http://www.ncbi.nlm.nih.gov/pubmed/18216705", "http://www.ncbi.nlm.nih.gov/pubmed/17992550", "http://www.ncbi.nlm.nih.gov/pubmed/17693524", "http://www.ncbi.nlm.nih.gov/pubmed/15253176"], "ideal_answer": ["Yes, FGFR3 mutation is associated with plagiocephaly. It is the most common mutation in plagiocephaly. FGFR genes have important effects on bone development, and mutations in 4 \"hot spot\" exons of FGFR1-3 are found in many patients with craniosynostosis and some with synostotic plagiocephaly."], "exact_answer": "yes", "type": "yesno", "id": "56c1f042ef6e394741000056", "snippets": [{"offsetInBeginSection": 251, "offsetInEndSection": 490, "text": "Series of neurosurgical interventions were carried out, principally for acrocephaly and posterior plagiocephaly. The most common achondroplasia mutation, a p.Gly380Arg in the fibroblast growth factor receptor 3 (FGFR3) gene, was detected. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23949953", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 335, "text": " The most common mutation for achondroplasia (FGFR3 Gly380Arg, resulting in 1138G>A) was identified. Imaging studies disclosed complex craniosynostosis and neurosurgical intervention was carried out, particularly for posterior plagiocephaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739570", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 33, "text": "FGFR mutations and plagiocephaly.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18216705", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "FGFR genes have important effects on bone development, and mutations in 4 \"hot spot\" exons of FGFR1-3 are found in many patients with craniosynostosis and some with synostotic plagiocephaly. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18216705", "endSection": "abstract"}, {"offsetInBeginSection": 1667, "offsetInEndSection": 1805, "text": "Mutation analyses in the FGFR3 gene revealed nucleotide alterations located in the mutational hot spot at amino acid residue 250 (g.C749).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17992550", "endSection": "abstract"}, {"offsetInBeginSection": 1014, "offsetInEndSection": 1351, "text": "RESULTS: In our cohort of 159 patients with various craniosynostosis syndromes, mutations were found in 100% of patients with Apert syndrome, 83.3% with Pfeiffer syndrome, 72.7% with Crouzon syndrome, 50.0% with Saethre-Chotzen syndrome, 27.7% with plagiocephaly, 31.8% with brachicephaly, 20% of complex cases, and 6.9% of mixed cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17693524", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 253, "text": "The genetic alterations that could cause unilateral coronal synostosis are more elusive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15253176", "endSection": "abstract"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1356, "text": "Mutations were found in eight of 47 patients: two patients with different single-amino-acid changes in FGFR2, three patients with FGFR3 Pro250Arg, and three patients with TWIST mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15253176", "endSection": "abstract"}, {"offsetInBeginSection": 1721, "offsetInEndSection": 1870, "text": "Other abnormalities in the craniofacial region and extremities were clues to a particular mutation in FGFR2, FGFR3, TWIST, or the X-linked mutation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15253176", "endSection": "abstract"}]}, {"body": "Does replication timing affect the rate of somatic mutations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23422670", "http://www.ncbi.nlm.nih.gov/pubmed/23821616", "http://www.ncbi.nlm.nih.gov/pubmed/22046001", "http://www.ncbi.nlm.nih.gov/pubmed/22114361", "http://www.ncbi.nlm.nih.gov/pubmed/22023572", "http://www.ncbi.nlm.nih.gov/pubmed/21666225", "http://www.ncbi.nlm.nih.gov/pubmed/19287383"], "ideal_answer": ["Mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome. All classes of substitutions are affected, suggesting a generalized mechanism involving replication time-dependent DNA damage. DNA repair systems, in general, are less efficient in late replicating heterochromatic regions compared to early replicating euchromatic regions of the genome. In yeast the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions. Limited evidence from one chromosome arm in Drosophila melanogaster suggests the opposite pattern, with regions overlapping early-firing origins showing increased levels of diversity and divergence. In humans DNA replication patterns help shape the mutational landscapes of normal and cancer genomes.", "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome", "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome", "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome", "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome", "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome", "Recent studies revealed a long suspected replication-timing effect on mutation rate, but the mechanisms that regulate the increase in mutation rate as the genome is replicated remain unclear. The mutations were distributed randomly throughout the genome, independent of replication timing. Here, we show that the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions. Interestingly, 5% of the single base pair substitutions might represent double-slippage events that occurred at the junction of immediately adjacent repeats, resulting in a shift in the repeat boundary."], "exact_answer": "yes", "type": "yesno", "id": "5710dd61cf1c32585100002e", "snippets": [{"offsetInBeginSection": 139, "offsetInEndSection": 324, "text": "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19287383", "endSection": "abstract"}, {"offsetInBeginSection": 327, "offsetInEndSection": 451, "text": "ll classes of substitutions are affected, suggesting a generalized mechanism involving replication time-dependent DNA damage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19287383", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 602, "text": "We show that mutation rate varies 6-fold across a single chromosome, that this variation is correlated with replication timing, and we propose a model to explain this variation that relies on the temporal separation of two processes for replicating past damaged DNA: error-free DNA damage tolerance and translesion synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21666225", "endSection": "abstract"}, {"offsetInBeginSection": 72, "offsetInEndSection": 264, "text": "Recent studies revealed a long suspected replication-timing effect on mutation rate, but the mechanisms that regulate the increase in mutation rate as the genome is replicated remain unclear. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023572", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 459, "text": "DNA repair systems, in general, are less efficient in late replicating heterochromatic regions compared to early replicating euchromatic regions of the genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023572", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "The mutational profile of the yeast genome is shaped by replication", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114361", "endSection": "title"}, {"offsetInBeginSection": 211, "offsetInEndSection": 340, "text": "the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114361", "endSection": "abstract"}, {"offsetInBeginSection": 728, "offsetInEndSection": 919, "text": "Thus, we show that the leading replicating strands present an excess of C over G and of A over T in the genome of S. cerevisiae (reciprocally an excess of G + T over C + A in lagging strands)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114361", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Late-replicating domains have higher divergence and diversity in Drosophila melanogaster", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22046001", "endSection": "title"}, {"offsetInBeginSection": 286, "offsetInEndSection": 382, "text": "Recent evidence also suggests that late replication is associated with high mutability in yeast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22046001", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 677, "text": "Limited evidence from one chromosome arm in Drosophila melanogaster suggests the opposite pattern, with regions overlapping early-firing origins showing increased levels of diversity and divergence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22046001", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 981, "text": "The mutation rate for DNA mismatch repair null strains was approximately 1 mutation per genome per generation, 225-fold greater than the wild-type rate. The mutations were distributed randomly throughout the genome, independent of replication timing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821616", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 218, "text": "Many single-nucleotide substitutions in cancer genomes arise because of errors in DNA replication, which is spatio-temporally stratified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 330, "text": "Here we propose that DNA replication patterns help shape the mutational landscapes of normal and cancer genomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 603, "text": "Using data on five fully sequenced cancer types and two personal genomes, we determined that the frequency of intergenic single-nucleotide substitution is significantly higher in late DNA replication timing regions, even after controlling for a number of genomic features", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670", "endSection": "abstract"}, {"offsetInBeginSection": 770, "offsetInEndSection": 930, "text": "we found that genomic regions in close spatial proximity to late-replicating domains display similar mutation spectra as the late-replicating regions themselves", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670", "endSection": "abstract"}]}, {"body": "Can bioprinting use human cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21358040"], "ideal_answer": ["Yes, human cells can be used for bioprinting"], "exact_answer": "yes", "type": "yesno", "id": "571394141174fb175500000b", "snippets": [{"offsetInBeginSection": 152, "offsetInEndSection": 273, "text": "In this study, human adipose-derived stem cells (hASCs) were printed in a free-scalable 3D grid pattern by means of LaBP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358040", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 777, "text": " Additionally, we provide the proof that even pre-differentiated hASCs could be utilized for the generation of 3D tissue grafts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358040", "endSection": "abstract"}]}, {"body": "Which is the treatment strategy followed in spinocerebellar ataxia type 3 for CAG removal?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23659897"], "ideal_answer": ["The novel treatment strategy proposed for treatment of Spinocerebellar ataxia type 3 is the removal of the toxic polyglutamine repeat from the ataxin-3 protein through antisense oligonucleotide-mediated exon skipping while maintaining important wild type functions of the protein."], "type": "summary", "id": "571394701174fb175500000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659897", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 288, "text": "Spinocerebellar ataxia type 3 is caused by a polyglutamine expansion in the ataxin-3 protein, resulting in gain of toxic function of the mutant protein. The expanded glutamine stretch in the protein is the result of a CAG triplet repeat expansion in the penultimate exon of the ATXN3 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659897", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 831, "text": "we propose a novel protein modification approach to reduce mutant ataxin-3 toxicity by removing the toxic polyglutamine repeat from the ataxin-3 protein through antisense oligonucleotide-mediated exon skipping while maintaining important wild type functions of the protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659897", "endSection": "abstract"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1184, "text": "exon skipping may be a novel therapeutic approach to reduce polyglutamine-induced toxicity in spinocerebellar ataxia type 3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659897", "endSection": "abstract"}]}, {"body": "What is the functional role of the protein Drp1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25332205", "http://www.ncbi.nlm.nih.gov/pubmed/25658204", "http://www.ncbi.nlm.nih.gov/pubmed/26038571", "http://www.ncbi.nlm.nih.gov/pubmed/25192600", "http://www.ncbi.nlm.nih.gov/pubmed/25237193", "http://www.ncbi.nlm.nih.gov/pubmed/24485837", "http://www.ncbi.nlm.nih.gov/pubmed/24631294", "http://www.ncbi.nlm.nih.gov/pubmed/25012575"], "ideal_answer": ["Dynamin-related protein 1 (Drp1) mediates mitochondrial fission.", "Drp1 is involved in the regulation of mitochondrial fission."], "exact_answer": [["mitochondrial fission"]], "type": "factoid", "id": "5717dbfe7de986d80d000001", "snippets": [{"offsetInBeginSection": 239, "offsetInEndSection": 318, "text": "dynamin-related protein 1 (Drp1), a GTPase that mediates mitochondrial fission,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25332205", "endSection": "abstract"}, {"offsetInBeginSection": 301, "offsetInEndSection": 389, "text": "dynamin-related protein 1 (DRP1), a protein required for mitochondrial network division.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25658204", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 370, "text": "dynamin-related protein 1 (Drp1)-mediated mitochondrial fission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26038571", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 192, "text": "Mitochondrial fission is mediated by dynamin-related protein 1 (Drp1),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25192600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Drp1 is a dynamin-like GTPase that mediates mitochondrial and peroxisomal division in a process dependent on self-assembly and coupled to GTP hydrolysis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237193", "endSection": "abstract"}, {"offsetInBeginSection": 521, "offsetInEndSection": 698, "text": "Mitochondrial fission requires the dynamin GTPase Drp1, which assembles in a ring around the mitochondrion and appears to constrict both outer and inner mitochondrial membranes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24485837", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 304, "text": "DRP1; a mitochondrial fission protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631294", "endSection": "abstract"}, {"offsetInBeginSection": 269, "offsetInEndSection": 446, "text": "Mitochondrial morphology is primarily controlled by the activation of dynamin-related proteins including dynamin-related protein 1 (Drp1), which promotes mitochondrial fission. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012575", "endSection": "abstract"}]}, {"body": "Which receptors are bound by Tasimelteon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25534555", "http://www.ncbi.nlm.nih.gov/pubmed/25423562", "http://www.ncbi.nlm.nih.gov/pubmed/25207602", "http://www.ncbi.nlm.nih.gov/pubmed/24610704", "http://www.ncbi.nlm.nih.gov/pubmed/24228714", "http://www.ncbi.nlm.nih.gov/pubmed/25422900"], "ideal_answer": ["Tasimelteon (HETLIOZ\u2122) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US for the treatment of non-24-hour sleep-wake disorder."], "exact_answer": [["MT1"], ["MT2"]], "type": "list", "id": "56c1f043ef6e394741000057", "snippets": [{"offsetInBeginSection": 124, "offsetInEndSection": 648, "text": "We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555", "endSection": "abstract"}, {"offsetInBeginSection": 413, "offsetInEndSection": 751, "text": "The drugs covered target GABAA (zaleplon-CR, lorediplon, EVT-201), orexin (filorexant, MIN-202), histamine-H1 (LY2624803), serotonin 5-HT2A (ITI-007), melatonin/serotonin5-HT1A (piromelatine) and melatonin (indication expansions of prolonged-release melatonin and tasimelteon for pediatric sleep and circadian rhythm disorders) receptors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25423562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Several melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) have recently become available for the treatment of insomnia, depression and circadian rhythms sleep-wake disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207602", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Tasimelteon (HETLIOZ\u2122) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US for the treatment of non-24-hour sleep-wake disorder. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 359, "text": "Numerous physiological functions of the pineal gland hormone melatonin are mediated via activation of two G-protein-coupled receptors, MT1 and MT2. The melatonergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and TIK-301, are high-affinity nonselective MT1/MT2 agonists. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714", "endSection": "abstract"}, {"offsetInBeginSection": 194, "offsetInEndSection": 326, "text": "A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25422900", "endSection": "abstract"}]}, {"body": "In which yeast chromosome does the rDNA cluster reside?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16738130", "http://www.ncbi.nlm.nih.gov/pubmed/8175878"], "ideal_answer": ["The rDNA cluster in Saccharomyces cerevisiae is located 450 kb from the left end and 610 kb from the right end of chromosome XII and consists of approximately 150 tandemly repeated copies of a 9.1 kb rDNA unit.", "Chromosome XII context is important for rDNA function in yeast", "Chromosome XII context is important for rDNA function in yeast", "Chromosome XII context is important for rDNA function in yeast", "Chromosome XII context is important for rDNA function in yeast", "Chromosome XII context is important for rDNA function in yeast", "Condensation of a unique region of chromosome XVI and the highly repetitive ribosomal DNA (rDNA) cluster from chromosome XII were also examined in budding yeast. The rDNA cluster in Saccharomyces cerevisiae is located 450 kb from the left end and 610 kb from the right end of chromosome XII and consists of approximately 150 tandemly repeated copies of a 9.1 kb rDNA unit. However, in cells arrested in late mitosis (M) by a cdc15 mutation, the unique DNA appeared decondensed while the repetitive rDNA region appeared condensed, suggesting that the condensation state of separate regions of the genome may be regulated differently. Finally our FISH method provides a new tool to analyze centromeres, telomeres, and gene expression in budding yeast."], "exact_answer": [["chromosome XII", "chromosome 12"]], "type": "factoid", "id": "5710e131a5ed216440000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Chromosome XII context is important for rDNA function in yeast", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738130", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The rDNA cluster in Saccharomyces cerevisiae is located 450 kb from the left end and 610 kb from the right end of chromosome XII and consists of approximately 150 tandemly repeated copies of a 9.1 kb rDNA unit", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738130", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 664, "text": "To explore the biological significance of this specific chromosomal context, chromosome XII was split at both sides of the rDNA cluster and strains harboring deleted variants of chromosome XII consisting of 450 kb, 1500 kb (rDNA cluster only) and 610 kb were created. In the strain harboring the 1500 kb variant of chromosome XII consisting solely of rDNA, the size of the rDNA cluster was found to decrease as a result of a decrease in rDNA copy number", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738130", "endSection": "abstract"}, {"offsetInBeginSection": 1255, "offsetInEndSection": 1456, "text": "These observations suggest that the context of chromosome XII plays an important role in maintaining a constant rDNA copy number and in physiological processes related to rDNA function in S.cerevisiae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738130", "endSection": "abstract"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1253, "text": "Notably, strains harboring the 450 kb chromosome XII variant and/or the 1500 kb variant consisting solely of rDNA had shorter life spans than wild type and also accumulated extrachromosomal rDNA circles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738130", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 720, "text": "Condensation of a unique region of chromosome XVI and the highly repetitive ribosomal DNA (rDNA) cluster from chromosome XII were also examined in budding yeast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8175878", "endSection": "abstract"}]}, {"body": "Could bioprinting be used in regenerative medicine against bone disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25866560", "http://www.ncbi.nlm.nih.gov/pubmed/25376489"], "ideal_answer": ["The developments in bioprinting (3D cell printing) techniques will be used in regenerative medicine and may allow the fabrication of customized implants for patients suffering in bone diseases in the future, once several technological limitations are addressed."], "exact_answer": "yes", "type": "yesno", "id": "5713968e1174fb175500000d", "snippets": [{"offsetInBeginSection": 561, "offsetInEndSection": 866, "text": "Before 3D Printing can be used routinely for the regeneration of complex tissues (e.g. bone, cartilage, muscles, vessels, nerves in the craniomaxillofacial complex), and complex organs with intricate 3D microarchitecture (e.g. liver, lymphoid organs), several technological limitations must be addressed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25866560", "endSection": "abstract"}, {"offsetInBeginSection": 714, "offsetInEndSection": 1463, "text": "It is expected that these new findings will give an innovation boost for the development of scaffolds for bone repair and reconstruction, which began with the use of bioinert materials, followed by bioactive materials and now leading to functional regenerative tissue units. These new developments have become possible with the discovery of the morphogenic activity of bioinorganic polymers, biocalcit, bio-polyphosphate and biosilica that are formed by a biogenic, enzymatic mechanism, a driving force along with the development of novel rapid-prototyping three-dimensional (3D) printing methods and bioprinting (3D cell printing) techniques that may allow a fabrication of customized implants for patients suffering in bone diseases in the future.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489", "endSection": "abstract"}]}, {"body": "Which disease phenotypes are associated to PRPS1 mutations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24528855", "http://www.ncbi.nlm.nih.gov/pubmed/23190330"], "ideal_answer": ["X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2) are allelic syndromes, caused by reduced activity of phosphoribosylpyrophosphate synthetase 1 (PRS-I) due to loss-of-function mutations in PRPS1."], "exact_answer": [["X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)"], ["Arts syndrome"], ["Non-syndromic sensorineural deafness (DFN2)"]], "type": "list", "id": "5713b0a51174fb175500000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with a novel PRPS1 mutation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24528855", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 272, "text": "X-linked Charcot-Marie-Tooth disease type 5 (CMTX5), Arts syndrome, and non-syndromic sensorineural deafness (DFN2) are allelic syndromes, caused by reduced activity of phosphoribosylpyrophosphate synthetase 1 (PRS-I) due to loss-of-function mutations in PRPS1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24528855", "endSection": "abstract"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1364, "text": "Our findings demonstrate that CMTX5, Arts syndrome and DFN2 are phenotypic clusters on an intrafamilial continuum, including overlapping phenotypes even within individuals. The respective phenotypic presentation seems to be determined by the exact PRPS1 mutation and the residual enzyme activity, the latter being largely influenced by the degree of skewed X-inactivation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24528855", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 491, "text": "Mutations in PRPS1 are associated with a spectrum of non-syndromic to syndromic hearing loss", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190330", "endSection": "abstract"}, {"offsetInBeginSection": 798, "offsetInEndSection": 1085, "text": "Gain of function mutations in PRPS1 cause a superactivity of the PRS-I protein whereas the loss-of-function mutations result in X-linked nonsyndromic sensorineural deafness type 2 (DFN2), or in syndromic deafness including Arts syndrome and X-linked Charcot-Marie-Tooth disease-5 (CMTX5)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190330", "endSection": "abstract"}]}, {"body": "What is known about diseases associated with mutations in the CHCHD10 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25428574", "http://www.ncbi.nlm.nih.gov/pubmed/25193783", "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "http://www.ncbi.nlm.nih.gov/pubmed/24934289"], "ideal_answer": ["Mutation c.197G>T p.G66V in CHCHD10 is the cause of the lower motor neuron syndrome LOSMoN/SMAJ. \nMutations in the CHCHD10 gene have been identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment.\nOther findings links CHCHD10 mutations to mitochondrial myopathy.", "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment."], "type": "summary", "id": "5717e0717de986d80d000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Late onset spinal motor neuronopathy is caused by mutation in CHCHD10.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25428574", "endSection": "title"}, {"offsetInBeginSection": 911, "offsetInEndSection": 1249, "text": "Mutation c.197G>T p.G66V in CHCHD10 is the cause of the lower motor neuron syndrome LOSMoN/SMAJ. During the preparation of this article other mutations were reported to cause frontotemporal dementia-amyotrophic lateral sclerosis syndrome, indicating that the CHCHD10 gene is largely important for the motor and cognitive neuronal systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25428574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193783", "endSection": "title"}, {"offsetInBeginSection": 1448, "offsetInEndSection": 1599, "text": "Our findings identify a novel gene causing mitochondrial myopathy, thereby expanding the spectrum of mitochondrial myopathies caused by nuclear genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193783", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 1458, "offsetInEndSection": 1783, "text": "The observation of a frontotemporal dementia-amyotrophic lateral sclerosis phenotype in a mitochondrial disease led us to analyse CHCHD10 in a cohort of 21 families with pathologically proven frontotemporal dementia-amyotrophic lateral sclerosis. We identified the same missense p.Ser59Leu mutation in one of these families. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24934289", "endSection": "abstract"}]}, {"body": "Selexipag is used for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26152132", "http://www.ncbi.nlm.nih.gov/pubmed/24392948", "http://www.ncbi.nlm.nih.gov/pubmed/25277144"], "ideal_answer": ["Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension."], "exact_answer": [["pulmonary arterial hypertension"]], "type": "factoid", "id": "56c1f045ef6e394741000058", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "OBJECTIVE: Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152132", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Selexipag for the treatment of pulmonary arterial hypertension.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392948", "endSection": "title"}, {"offsetInBeginSection": 107, "offsetInEndSection": 253, "text": "This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392948", "endSection": "abstract"}, {"offsetInBeginSection": 789, "offsetInEndSection": 1030, "text": "Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392948", "endSection": "abstract"}, {"offsetInBeginSection": 1179, "offsetInEndSection": 1314, "text": "Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392948", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "OBJECTIVE: The objective of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in development for pulmonary arterial hypertension in healthy subjects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25277144", "endSection": "abstract"}]}, {"body": "How does Rif1 regulate DNA replication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24656819", "http://www.ncbi.nlm.nih.gov/pubmed/24685139", "http://www.ncbi.nlm.nih.gov/pubmed/24462468", "http://www.ncbi.nlm.nih.gov/pubmed/24634216", "http://www.ncbi.nlm.nih.gov/pubmed/24879017", "http://www.ncbi.nlm.nih.gov/pubmed/23809990", "http://www.ncbi.nlm.nih.gov/pubmed/22279046", "http://www.ncbi.nlm.nih.gov/pubmed/22850673", "http://www.ncbi.nlm.nih.gov/pubmed/22850674", "http://www.ncbi.nlm.nih.gov/pubmed/19948482", "http://www.ncbi.nlm.nih.gov/pubmed/15342490"], "ideal_answer": ["Rif1 (Rap1-interacting-factor-1), originally identified as a telomere-binding factor in yeast, is a critical determinant of the replication timing programme in human cells. Rif1 tightly binds to nuclear-insoluble structures at late-M-to-early-G1 and regulates chromatin-loop sizes. Furthermore, Rif1 colocalizes specifically with the mid-S replication foci. Thus, Rif1 establishes the mid-S replication domains that are restrained from being activated at early-S-phase. Overall, Rif1 plays crucial roles in determining the replication timing domain structures in human cells through regulating higher-order chromatin architecture. This function of Rif1 depends on its interaction with PP1 phosphatases and the PP1/Rif1 interaction is downregulated by the phosphorylation of Rif1, most likely by CDK/DDK."], "type": "summary", "id": "5710ed19a5ed216440000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Protein phosphatase 1 recruitment by Rif1 regulates DNA replication origin firing by counteracting DDK activity", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24656819", "endSection": "title"}, {"offsetInBeginSection": 110, "offsetInEndSection": 401, "text": "Yeast Rif1 associates with telomeres and regulates their length. In contrast, human Rif1 did not accumulate at functional telomeres, but localized to dysfunctional telomeres and to telomeric DNA clusters in ALT cells, a pattern of telomere association typical of DNA-damage-response factors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342490", "endSection": "abstract"}, {"offsetInBeginSection": 402, "offsetInEndSection": 523, "text": "After induction of double-strand breaks (DSBs), Rif1 formed foci that colocalized with other DNA-damage-response factors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342490", "endSection": "abstract"}, {"offsetInBeginSection": 974, "offsetInEndSection": 1168, "text": "These data reveal that human Rif1 contributes to the ATM-mediated protection against DNA damage and point to a remarkable difference in the primary function of this protein in yeast and mammals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Mammalian Rif1 contributes to replication stress survival and homology-directed repair.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948482", "endSection": "title"}, {"offsetInBeginSection": 359, "offsetInEndSection": 563, "text": "Rif1 deficiency leads to failure in embryonic development, and conditional deletion of Rif1 from mouse embryo fibroblasts affects S-phase progression, rendering cells hypersensitive to replication poisons", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948482", "endSection": "abstract"}, {"offsetInBeginSection": 565, "offsetInEndSection": 688, "text": "Rif1 deficiency does not alter the activation of the DNA replication checkpoint but rather affects the execution of repair.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948482", "endSection": "abstract"}, {"offsetInBeginSection": 856, "offsetInEndSection": 1112, "text": "Consistent with a role in S-phase progression, Rif1 accumulates at stalled replication forks, preferentially around pericentromeric heterochromatin. Collectively, these findings reveal a function for Rif1 in the repair of stalled forks by facilitating HDR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948482", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Rif1 regulates the replication timing domains on the human genome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850674", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 449, "text": " Rif1 (Rap1-interacting-factor-1), originally identified as a telomere-binding factor in yeast, is a critical determinant of the replication timing programme in human cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850674", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 642, "text": "Depletion of Rif1 results in specific loss of mid-S replication foci profiles, stimulation of initiation events in early-S-phase and changes in long-range replication timing domain structures", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850674", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 987, "text": "Rif1 tightly binds to nuclear-insoluble structures at late-M-to-early-G1 and regulates chromatin-loop sizes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850674", "endSection": "abstract"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1353, "text": "Rif1 colocalizes specifically with the mid-S replication foci. Thus, Rif1 establishes the mid-S replication domains that are restrained from being activated at early-S-phase. Our results indicate that Rif1 plays crucial roles in determining the replication timing domain structures in human cells through regulating higher-order chromatin architecture.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850674", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 261, "text": "mouse Rif1 as a key player in the regulation of DNA replication timin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850673", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Mouse Rif1 is a key regulator of the replication-timing programme in mammalian cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850673", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 392, "text": "Rif1 deficiency in primary cells results in an unprecedented global alteration of the temporal order of replication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850673", "endSection": "abstract"}, {"offsetInBeginSection": 453, "offsetInEndSection": 623, "text": "Rif1 deletion and is neither accompanied by alterations in the transcriptional landscape nor by major changes in the biochemical identity of constitutive heterochromatin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850673", "endSection": "abstract"}, {"offsetInBeginSection": 637, "offsetInEndSection": 744, "text": "Rif1 deficiency leads to both defective G1/S transition and chromatin re-organization after DNA replication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22850673", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Rif1 is a global regulator of timing of replication origin firing in fission yeast", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22279046", "endSection": "title"}, {"offsetInBeginSection": 301, "offsetInEndSection": 436, "text": "We identified rif1\u0394, a null mutant of rif1(+), a conserved telomere-binding factor, as an efficient bypass mutant of fission yeast hsk1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22279046", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 687, "text": "At the same time, many early-firing, efficient origins are suppressed or delayed in firing timing in rif1\u0394", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22279046", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 945, "text": "Rif1 binds not only to telomeres, but also to many specific locations on the arm segments that only partially overlap with the prereplicative complex assembly sites, although Rif1 tends to bind in the vicinity of the late/dormant origins activated in rif1\u0394", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22279046", "endSection": "abstract"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1256, "text": "Rif1 is a critical determinant of the origin activation program on the fission yeast chromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22279046", "endSection": "abstract"}, {"offsetInBeginSection": 55, "offsetInEndSection": 103, "text": "Rif1 as a global regulator of replication timing", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23809990", "endSection": "title"}, {"offsetInBeginSection": 433, "offsetInEndSection": 556, "text": "Rif1 which plays crucial roles in the regulation of the replication timing program in yeast as well as in higher eukaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23809990", "endSection": "abstract"}, {"offsetInBeginSection": 558, "offsetInEndSection": 849, "text": "In mammalian cells, Rif1 appears to regulate the structures of replication timing domains through its ability to organize chromatin loop structures. Regulation of chromatin architecture by Rif1 may be linked to other chromosome transactions including recombination, repair, or transcription.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23809990", "endSection": "abstract"}, {"offsetInBeginSection": 468, "offsetInEndSection": 590, "text": "Rif1 has recently been identified as a genome-wide regulator of replication timing in fission yeast and in mammalian cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24879017", "endSection": "abstract"}, {"offsetInBeginSection": 592, "offsetInEndSection": 807, "text": "However, previous studies in budding yeast have suggested that Rif1's role in controlling replication timing may be limited to subtelomeric domains and derives from its established role in telomere length regulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24879017", "endSection": "abstract"}, {"offsetInBeginSection": 809, "offsetInEndSection": 1003, "text": "We have analyzed replication timing by analyzing BrdU incorporation genome-wide, and report that Rif1 regulates the timing of late/dormant replication origins throughout the S. cerevisiae genome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24879017", "endSection": "abstract"}, {"offsetInBeginSection": 1397, "offsetInEndSection": 1482, "text": "Rif1 regulates replication timing through a mechanism independent of this checkpoint.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24879017", "endSection": "abstract"}, {"offsetInBeginSection": 1509, "offsetInEndSection": 1874, "text": "the Rif1 mechanism regulates origin timing irrespective of proximity to a chromosome end, and suggest instead that telomere sequences merely provide abundant binding sites for proteins that recruit Rif1. Still, the abundance of Rif1 binding in telomeric domains may facilitate Rif1-mediated repression of non-telomeric origins that are more distal from centromeres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24879017", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Rif1 controls DNA replication by directing Protein Phosphatase 1 to reverse Cdc7-mediated phosphorylation of the MCM complex", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24532715", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 473, "text": "Mammalian Rif1 is a key regulator of DNA replication timing, double-stranded DNA break repair, and replication fork restart. Dissecting the molecular functions of Rif1 is essential to understand how it regulates such diverse processes. However, Rif1 is a large protein that lacks well defined functional domains and is predicted to be largely intrinsically disordered; these features have hampered recombinant expression of Rif1 and subsequent functional characterization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24634216", "endSection": "abstract"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1371, "text": "the first structural study of the mammalian Rif1, identifying a domain that directly links its function to DNA binding. The high specificity of Rif1 for cruciform structures is significant given the role of this key protein in regulating origin firing and DNA repair.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24634216", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "RIF1: a novel regulatory factor for DNA replication and DNA damage response signaling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462468", "endSection": "title"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1216, "text": "Rif1 is conserved from yeast to humans but its function has evolved from telomere length regulation in yeast to the maintenance of genome integrity in mammalian cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462468", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1390, "text": "Recently its role in the maintenance of genomic integrity has been expanded to include the regulation of chromatin structure, replication timing and intra-S phase checkpoint", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462468", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 264, "text": "budding yeast Rif1 protein inhibits activation of prereplication complexes (pre-RCs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "The Rif1 protein, originally identified as a telomere-binding factor in yeast, has recently been implicated in DNA replication control from yeast to metazoans", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Rif1 controls DNA replication timing in yeast through the PP1 phosphatase Glc7", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685139", "endSection": "title"}, {"offsetInBeginSection": 630, "offsetInEndSection": 1068, "text": "Rif1 also interacts with Dbf4 in yeast two-hybrid assays, further implicating this protein in direct modulation of pre-RC activation through the DDK. Finally, we demonstrate Rif1 RVxF/SILK motif-dependent recruitment of Glc7 to telomeres and earlier replication of these regions in cells where the motifs are mutated. Our data thus link Rif1 to negative regulation of replication origin firing through recruitment of the Glc7 phosphatase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685139", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 427, "text": "Rif1, originally identified as a telomeric protein, was recently implicated in specifying replication timing in yeast and mammals. We show that this function of Rif1 depends on its interaction with PP1 phosphatases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24656819", "endSection": "abstract"}, {"offsetInBeginSection": 688, "offsetInEndSection": 977, "text": "Our data suggest that the PP1/Rif1 interaction is downregulated by the phosphorylation of Rif1, most likely by CDK/DDK. These findings elucidate the mechanism of action of Rif1 in the control of DNA replication and demonstrate a role of PP1 phosphatases in the regulation of origin firing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24656819", "endSection": "abstract"}]}, {"body": "For the constructions of which organs has 3D printing been tested?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25281749", "http://www.ncbi.nlm.nih.gov/pubmed/25197745", "http://www.ncbi.nlm.nih.gov/pubmed/23635097"], "ideal_answer": ["Nose, ear and meniscus prototypes/constructs have been produced with 3D (3-dimesional) printing."], "exact_answer": [["nose"], ["ear"], ["meniscus"]], "type": "list", "id": "5713bf261174fb1755000011", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 245, "text": "To determine the potential of an integrated, image-based computer-aided design (CAD) and 3-dimensional (3D) printing approach to engineer scaffolds for head and neck cartilaginous reconstruction for auricular and nasal reconstruction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25281749", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 867, "text": "Subcutaneous in vivo implantation of auricular and nasal scaffolds was performed in a porcine model.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25281749", "endSection": "abstract"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1616, "text": "Auricular and nasal constructs with several types of microporous architecture were rapidly manufactured with high fidelity to human patient anatomy. Subcutaneous in vivo implantation of auricular and nasal scaffolds resulted in an excellent appearance and complete soft tissue ingrowth. Histological analysis of in vitro scaffolds demonstrated native-appearing cartilaginous growth that respected the boundaries of the scaffold.CONCLUSION: Integrated, image-based CAD and 3D printing processes generated patient-specific nasal and auricular scaffolds that supported cartilage regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25281749", "endSection": "abstract"}, {"offsetInBeginSection": 827, "offsetInEndSection": 929, "text": "A prototype meniscus cartilage was prepared to illustrate the potential application in bioengineering.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25197745", "endSection": "abstract"}, {"offsetInBeginSection": 567, "offsetInEndSection": 1148, "text": "As a proof of concept, we generated a bionic ear via 3D printing of a cell-seeded hydrogel matrix in the anatomic geometry of a human ear, along with an intertwined conducting polymer consisting of infused silver nanoparticles. This allowed for in vitro culturing of cartilage tissue around an inductive coil antenna in the ear, which subsequently enables readout of inductively-coupled signals from cochlea-shaped electrodes. The printed ear exhibits enhanced auditory sensing for radio frequency reception, and complementary left and right ears can listen to stereo audio music. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23635097", "endSection": "abstract"}]}, {"body": "Which phenotypes are associated with heterozygous mutations of the BSCL2 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20806400", "http://www.ncbi.nlm.nih.gov/pubmed/17663003"], "ideal_answer": ["Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement.", "Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement", "Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement", "Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement", "Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement", "Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement"], "exact_answer": [["Silver syndrome/spastic paraplegia 17"], ["Distal hereditary motor neuropathy type V"], ["Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement"]], "type": "list", "id": "5713b29f1174fb175500000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 313, "text": "Heterozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene have been associated with different clinical phenotypes including Silver syndrome/spastic paraplegia 17, distal hereditary motor neuropathy type V, and Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20806400", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 392, "text": "Distal hereditary motor neuropathy type V (dHMN-V) and Charcot-Marie-Tooth syndrome (CMT) type 2 presenting with predominant hand involvement, also known as CMT2D and Silver syndrome (SS) are rare phenotypically overlapping diseases which can be caused by mutations in the Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2) and in the glycyl-tRNA synthetase encoding (GARS) genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663003", "endSection": "abstract"}]}, {"body": "Is the SDHAF2 gene  encoding a protein necessary for flavination of SDHA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23061808", "http://www.ncbi.nlm.nih.gov/pubmed/21752896"], "ideal_answer": ["Yes, SDHAF2 is required for flavination of SDHA.", "Yes, SDHAF2 or hSDH5, is the gene encoding the enzyme responsible for the flavination of SDHA."], "exact_answer": "yes", "type": "yesno", "id": "5717fb557de986d80d000009", "snippets": [{"offsetInBeginSection": 635, "offsetInEndSection": 721, "text": "the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 196, "text": "SDHAF2, required for flavination of SDHA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896", "endSection": "abstract"}]}, {"body": "How does Hst5 (histatin 5) affect infections by Candida glabrata?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24247141", "http://www.ncbi.nlm.nih.gov/pubmed/23613860", "http://www.ncbi.nlm.nih.gov/pubmed/16495279", "http://www.ncbi.nlm.nih.gov/pubmed/11442851", "http://www.ncbi.nlm.nih.gov/pubmed/10049295", "http://www.ncbi.nlm.nih.gov/pubmed/9333052"], "ideal_answer": ["Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva. Histatin 5, a human salivary protein with broad-spectrum antifungal activity, is remarkably ineffective against Candida glabrata. Histatin 5 (Hst 5) is a small cationic human salivary peptide with high fungicidal activity against C. albicans, however many strains of C. glabrata are resistant. Since Hst 5 requires fungal binding to cell wall components prior to intracellular translocation, reduced Hst 5 binding to C. glabrata may be the reason for its insensitivity. Hst 5 enters C. albicans cell through polyamine transporters Dur3p and Dur31p that are uncharacterized in C. glabrata. The crucial rate limiting step is reduced uptake that can be overcome by expression of C. albicans Dur proteins in C. glabrata.", "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva", "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva", "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva", "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva", "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva", "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva. We found that Hst 54-15-Spd was significantly more effective in killing C. albicans and Candida glabrata than Hst 5 alone in both planktonic and biofilm growth and that Hst 54-15-Spd retained high activity in both serum and saliva. Histatin 5 (Hst 5) is a small cationic human salivary peptide with high fungicidal activity against C. albicans, however many strains of C. glabrata are resistant. We constructed a conjugate peptide using spermidine (Spd) linked to the active fragment of Hst 5 (Hst 54-15), based upon our findings that C. albicans spermidine transporters are required for Hst 5 uptake and fungicidal activity.", "Our results, taken together, demonstrated that histatin-5 possessed the fungicidal activity against Candida species other than C. glabrata. "], "type": "summary", "id": "5710eec5a5ed216440000004", "snippets": [{"offsetInBeginSection": 247, "offsetInEndSection": 389, "text": "Human salivary histatins, including histatin 5 (Hst 5), are small cationic proteins that are the major source of fungicidal activity of saliva", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247141", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 257, "text": "Histatin 5 (Hst 5) is a small cationic human salivary peptide with high fungicidal activity against C. albicans, however many strains of C. glabrata are resistant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613860", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 433, "text": "Since Hst 5 requires fungal binding to cell wall components prior to intracellular translocation, reduced Hst 5 binding to C. glabrata may be the reason for its insensitivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613860", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 944, "text": "Hst 5 enters C. albicans cell through polyamine transporters Dur3p and Dur31p that are uncharacterized in C. glabrata. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613860", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1279, "text": "the crucial rate limiting step is reduced uptake that can be overcome by expression of C. albicans Dur proteins in C. glabrata.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Histatin 5, a human salivary protein with broad-spectrum antifungal activity, is remarkably ineffective against Candida glabrata.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16495279", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 498, "text": "Our results, taken together, demonstrated that histatin-5 possessed the fungicidal activity against Candida species other than C. glabrata.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11442851", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 360, "text": "The present study shows that a number of basic antifungal peptides, including human salivary histatin 5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant Candida glabrata isolate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10049295", "endSection": "abstract"}, {"offsetInBeginSection": 770, "offsetInEndSection": 886, "text": "In addition, we tested azole-resistant C. albicans and Candida glabrata strains for their susceptibilities to Hsn-5.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9333052", "endSection": "abstract"}, {"offsetInBeginSection": 1385, "offsetInEndSection": 1727, "text": "Assessment of the candidacidal activity of Hsn-5 with the well-characterized azole-resistant strains of C. albicans and C. glabrata, however, suggested that the mode of action of histatins against Candida is distinct from that of azole-based antifungal agents because Hsn-5 kills both azole-sensitive and azole-resistant strains equally well.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9333052", "endSection": "abstract"}]}, {"body": "Is the SDHAF2 gene encoding a protein necessary for flavination of SDHA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21752896", "http://www.ncbi.nlm.nih.gov/pubmed/23061808"], "ideal_answer": ["Yes, SDHAF2 or hSDH5, is the gene encoding the enzyme responsible for the flavination of SDHA.", "Yes, SDHAF2 is required for flavination of SDHA."], "exact_answer": "yes", "type": "yesno", "id": "571e06447de986d80d000016", "snippets": [{"offsetInBeginSection": 9, "offsetInEndSection": 198, "text": "Pheochromocytoma-paraganglioma syndrome is caused by mutations in SDHB, SDHC, and SDHD, encoding subunits of succinate dehydrogenase (SDH), and in SDHAF2, required for flavination of SDHA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896", "endSection": "abstract"}, {"offsetInBeginSection": 381, "offsetInEndSection": 786, "text": "At present, these are RET proto-oncogene, von Hippel-Lindau disease tumor suppressor gene (VHL), neurofibromatosis type 1 tumor suppressor gene (NF1), genes encoding the succinate dehydrogenase (SDH) complex subunits SDHB, SDHC, and SDHD, but also SDHA, the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5), and the newly described TMEM127 and MAX tumor suppressor genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808", "endSection": "abstract"}]}, {"body": "Which genes are associated with autosomal dominant Charcot-Marie-Tooth?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25326399", "http://www.ncbi.nlm.nih.gov/pubmed/24894446", "http://www.ncbi.nlm.nih.gov/pubmed/21199105", "http://www.ncbi.nlm.nih.gov/pubmed/18231710", "http://www.ncbi.nlm.nih.gov/pubmed/18975529", "http://www.ncbi.nlm.nih.gov/pubmed/17052987", "http://www.ncbi.nlm.nih.gov/pubmed/17636067", "http://www.ncbi.nlm.nih.gov/pubmed/16775366", "http://www.ncbi.nlm.nih.gov/pubmed/15731758", "http://www.ncbi.nlm.nih.gov/pubmed/15099592", "http://www.ncbi.nlm.nih.gov/pubmed/12525712", "http://www.ncbi.nlm.nih.gov/pubmed/12481988"], "ideal_answer": ["The genes associated with the X-linked and the autosomal dominant forms of Charcot-Marie-Tooth disease are GJB1, MPZ, INF2, DNM2, YARS, GNB4, NEFL, MFN2, LRSAM1, GDAP1, PMP22, LITAF, and EGR2. Identification of these genes has not only been important for patients and families, but also provided new information about disease pathogenesis."], "exact_answer": [["GJB1"], ["MPZ"], ["INF2"], ["DNM2"], ["YARS"], ["GNB4"], ["NEFL"], ["MFN2"], ["LRSAM1"], ["GDAP1"], ["PMP22"], ["LITAF"], ["EGR2"]], "type": "list", "id": "5713bc991174fb1755000010", "snippets": [{"offsetInBeginSection": 505, "offsetInEndSection": 853, "text": " GJB1 is currently considered to be associated with X-linked DI-CMT, and MPZ, INF2, DNM2, YARS, GNB4, NEFL, and MFN2 are associated with autosomal DI-CMT. Moreover, GDAP1, KARS, and PLEKHG5 are associated with RI-CMT. Identification of these genes is not only important for patients and families but also provides new information about pathogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326399", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894446", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 642, "text": "Charcot-Marie-Tooth disease (CMT) refers to a heterogeneous group of genetic motor and sensory neuropathies. According to the primary site of damage, a distinction is made between demyelinating and axonal forms (CMT1 and 2, respectively, when inherited as an autosomal dominant trait). Leucine-rich repeat and sterile alpha motif-containing protein 1 (LRSAM1) is a ubiquitin-protein ligase with a role in sorting internalised cell-surface receptor proteins. So far, mutations in the LRSAM1 gene have been shown to cause axonal CMT in three different families and can confer either dominant or recessive transmission of the disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894446", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 750, "text": "We have identified a novel mutation in LRSAM1 in a small family with dominant axonal CMT", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894446", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Phenotypical features of the p.R120W mutation in the GDAP1 gene causing autosomal dominant Charcot-Marie-Tooth disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199105", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 318, "text": "Mutations in the ganglioside-induced-differentiation-associated protein 1 gene (GDAP1) can cause Charcot-Marie-Tooth (CMT) disease with demyelinating (CMT4A) or axonal forms (CMT2K and ARCMT2K). Most of these mutations present a recessive inheritance, but few autosomal dominant GDAP1 mutations have also been reported", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199105", "endSection": "abstract"}, {"offsetInBeginSection": 1309, "offsetInEndSection": 1460, "text": " Our findings highlight the relevance of dominantly transmitted p.R120W GDAP1 gene mutations which can cause an axonal CMT with a wide clinical profile", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18231710", "endSection": "title"}, {"offsetInBeginSection": 279, "offsetInEndSection": 361, "text": "There have been very few reports of GDAP1 mutations in autosomal dominant (AD) CMT", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18231710", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 441, "text": "Here, we report an AD CMT family with a novel Q218E mutation in the GDAP1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18231710", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 948, "text": "CMT type 1 (CMT1; MIM 118200) is a group of autosomal dominant-inherited demyelinating neuropathies with a disease onset at or after childhood. Five different subtypes have been identified based on different causative genes. Among them, CMT1A (MIM #118220) is most common and is usually associated with a duplication of a 1.5-Mb region on chromosome 17p11.2, which includes peripheral myelin protein 22 gene (PMP22; MIM *601097)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18975529", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 358, "text": "Mutations in the NF-L gene (NEFL) cause autosomal dominant neuropathies that are classified either as axonal Charcot-Marie-Tooth (CMT) type 2E (CMT2E) or demyelinating CMT type 1F (CMT1F)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17052987", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 249, "text": "Recently, mutations affecting different domains of dynamin-2 (DNM2) were associated alternatively with autosomal dominant centronuclear myopathy or dominant intermediate (demyelinating and axonal) Charcot-Marie-Tooth disease (CMT) type B", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17636067", "endSection": "abstract"}, {"offsetInBeginSection": 978, "offsetInEndSection": 1203, "text": "Four genes (PMP22, MPZ, LITAF, and EGR2) have been described in the last 15 yr associated with AD CMTI and a further gene (NEFL), originally described as causing AD CMT2 can also cause AD CMT1 (by neurophysiological criteria)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775366", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15731758", "endSection": "title"}, {"offsetInBeginSection": 248, "offsetInEndSection": 519, "text": "We refined the locus associated with DI-CMTB on chromosome 19p12-13.2 to 4.2 Mb in three unrelated families with CMT originating from Australia, Belgium and North America. After screening candidate genes, we identified unique mutations in dynamin 2 (DNM2) in all families", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15731758", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 442, "text": "Here, we report a large family showing characteristic phenotypes of Charcot-Marie-Tooth type 1A along with deafness in an autosomal dominant fashion. We detected a sequence variation (c.68C>G) co-segregating with the disease phenotype and leading to a T23R missense mutation in PMP22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15099592", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 249, "text": "The authors recently mapped an autosomal dominant demyelinating form of CMT type 1 (CMT1C) to chromosome 16p13.1-p12.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12525712", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 900, "text": "The authors identified missense mutations (G112S, T115N, W116G) in the LITAFgene (lipopolysaccharide-induced tumor necrosis factor-alpha factor) in three CMT1C pedigrees", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12525712", "endSection": "abstract"}, {"offsetInBeginSection": 613, "offsetInEndSection": 846, "text": "We identified a novel neurofilament-light missense mutation (C64T) that causes the disease in a large Slovenian CMT2 family. This novel mutation shows complete co-segregation with the dominantly inherited CMT2 phenotype in our family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12481988", "endSection": "abstract"}]}, {"body": "List inflammatory caspase proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25943872", "http://www.ncbi.nlm.nih.gov/pubmed/24280500", "http://www.ncbi.nlm.nih.gov/pubmed/23215645", "http://www.ncbi.nlm.nih.gov/pubmed/22895188", "http://www.ncbi.nlm.nih.gov/pubmed/20541850", "http://www.ncbi.nlm.nih.gov/pubmed/21880711", "http://www.ncbi.nlm.nih.gov/pubmed/22195746", "http://www.ncbi.nlm.nih.gov/pubmed/21051981", "http://www.ncbi.nlm.nih.gov/pubmed/20401526", "http://www.ncbi.nlm.nih.gov/pubmed/20401456", "http://www.ncbi.nlm.nih.gov/pubmed/20514521", "http://www.ncbi.nlm.nih.gov/pubmed/19927353"], "ideal_answer": ["caspase-1\ncaspase-4\ncaspase-5"], "exact_answer": [["caspase-1"], ["caspase-4"], ["caspase-5"]], "type": "list", "id": "571cd9537de986d80d00000e", "snippets": [{"offsetInBeginSection": 1291, "offsetInEndSection": 1524, "text": " In addition to identifying caspases-4 and -5 as potential targets for limiting intestinal inflammation, this study has identified epithelial-expressed caspases-4 and -5 as biomarkers with diagnostic and therapeutic potential in CRC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943872", "endSection": "abstract"}, {"offsetInBeginSection": 344, "offsetInEndSection": 607, "text": "However, the involvement of two related inflammatory caspase members, caspases-4 and -5, during intestinal homeostasis and disease has not yet been established. This study demonstrates that caspases-4 and -5 are involved in IBD-associated intestinal inflammation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943872", "endSection": "abstract"}, {"offsetInBeginSection": 157, "offsetInEndSection": 342, "text": "Altered activity of caspases, particularly caspase-1, has been implicated in the development of intestinal diseases, such as inflammatory bowel disease (IBD) and colorectal cancer (CRC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943872", "endSection": "abstract"}, {"offsetInBeginSection": 416, "offsetInEndSection": 559, "text": "In contrast, engagement of various PRR in the recently identified inflammasome complexes lead to activation of a cysteine protease, caspase-1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24280500", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 331, "text": "ctivation of inflammatory caspase proteases. One such caspase, CASPASE-1 (CASP1), ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23215645", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Inflammasomes are cytosolic multiprotein complexes assembled by intracellular nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and they initiate innate immune responses to invading pathogens and danger signals by activating caspase-1 (ref. 1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895188", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 611, "text": "e activation of inflammasome by different stimuli triggers the proteolytic cleavage of pro-caspase 1 into active caspase 1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20541850", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 377, "text": "Formation of the inflammasome can lead to the activation of inflammatory caspases, such as Caspase-1, which then activate pro-inflammatory cytokines by proteolytic cleavage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880711", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 503, "text": "inflammatory caspase-1 ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22195746", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 675, "text": "Human caspase-5 is classified as an inflammatory caspase, although its substrate has not been identified yet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051981", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 712, "text": "e inflammatory Caspase-1 ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20401526", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 855, "text": "the inflammatory caspase-1 ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20401456", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Although it is conventionally regarded as an inflammatory caspase, recent studies have shown that caspase-4 plays a role in induction of apoptosis by endoplasmic reticulum (ER) stress. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514521", "endSection": "abstract"}]}, {"body": "Which antibiotics target peptidoglycan biosynthesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22280885", "http://www.ncbi.nlm.nih.gov/pubmed/22815801", "http://www.ncbi.nlm.nih.gov/pubmed/21091161", "http://www.ncbi.nlm.nih.gov/pubmed/21867549", "http://www.ncbi.nlm.nih.gov/pubmed/18558445", "http://www.ncbi.nlm.nih.gov/pubmed/16832063", "http://www.ncbi.nlm.nih.gov/pubmed/12197711", "http://www.ncbi.nlm.nih.gov/pubmed/12440876", "http://www.ncbi.nlm.nih.gov/pubmed/10801476", "http://www.ncbi.nlm.nih.gov/pubmed/9210483", "http://www.ncbi.nlm.nih.gov/pubmed/8891144", "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "http://www.ncbi.nlm.nih.gov/pubmed/2334153"], "ideal_answer": ["Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice. Cells treated with ampicillin, D-cycloserine, or fosfomycin had only one chloroplast after cell division, suggesting that the cells divided without chloroplast division. The antibiotics bacitracin and vancomycin showed no obvious effect. Colchicine inhibits Closterium cell elongation after division.  Surprisingly, also cinnamycin of Streptomyces cinnamoneus cinnamoneus), previously known to bind specifically to phosphatidylethanolamin of biological membranes, provoked strong cell wall biosynthetic stress. Other substances include fluorescent derivatives of two PG-binding antibiotics, vancomycin and ramoplanin. The muraymycins constitute a new antibiotic family whose core structure contains a glycosylated uronic acid derivative joined by an aminopropane group to a hexahydro-2-imino-4-pyrimidylglycyl residue (epicapreomycidine) containing dipeptide that is further extended by a urea-valine moiety. The muraymycins inhibited peptidoglycan biosynthesis. Ramoplanin is a cyclicdepsipeptide antibiotic that inhibits peptidoglycan biosynthesis. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Ramoplanin, a new lipoglycopeptide antibiotic, inhibits cell wall peptidoglycan biosynthesis in gram-positive bacteria.", "Under some conditions, both ramoplanin and vancomycin probes produce helicoid staining patterns along the cylindrical walls of B. subtilis cells. This work has implications for the design of ramoplanin derivatives and may influence how other proposed substrate binding antibiotics are studied. This was confirmed by in vitro studies involving a wall-membrane particulate fraction from Gaffkya homari in which peptidoglycan synthesis from UDP-MurNAc-tetrapeptide was inhibited by ramoplanin but not by vancomycin. New results support a two-state model for septal and peripheral PG synthesis at mid-cell, involvement of essential cell division proteins in PG remodeling, and mid-cell localization of proteins that organize PG biosynthesis and that form the protein translocation apparatus."], "exact_answer": [["colchicine"], ["fosfomycin"], ["bacitracin"], ["vancomycin"], ["D-cycloserine", "seromycin"], ["ampicillin"], ["cinnamycin"], ["ramoplanin"], ["muraymycin"], ["mersacidin"]], "type": "list", "id": "571529efcb4ef8864c000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Treatment with antibiotics that interfere with peptidoglycan biosynthesis inhibits chloroplast division in the desmid Closterium", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815801", "endSection": "title"}, {"offsetInBeginSection": 247, "offsetInEndSection": 360, "text": "To detect cells just after division, we used colchicine, which inhibits Closterium cell elongation after division", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815801", "endSection": "abstract"}, {"offsetInBeginSection": 618, "offsetInEndSection": 685, "text": "The antibiotics bacitracin and vancomycin showed no obvious effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815801", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 616, "text": "cells treated with ampicillin, D-cycloserine, or fosfomycin had only one chloroplast after cell division, suggesting that the cells divided without chloroplast division", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815801", "endSection": "abstract"}, {"offsetInBeginSection": 67, "offsetInEndSection": 245, "text": "We investigated the effects of antibiotics that interfere with peptidoglycan biosynthesis on chloroplast division in the desmid Closterium peracerosum-strigosum-littorale complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815801", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22280885", "endSection": "title"}, {"offsetInBeginSection": 418, "offsetInEndSection": 657, "text": "Of late, the peptidoglycan (PG) layer, the most important component of the bacterial cell wall has been the subject of drug targeting because, first, it is essential for the survivability of eubacteria and secondly, it is absent in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091161", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 129, "text": "Antibiotics which inhibit bacterial peptidoglycan biosynthesis are the most widely used in current clinical practice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21867549", "endSection": "abstract"}, {"offsetInBeginSection": 1587, "offsetInEndSection": 1710, "text": "A dose-response experiment with an E. coli strain susceptible to ampicillin demonstrated a weak effect before the MIC dose.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21867549", "endSection": "abstract"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1408, "text": " In an initial approach, the procedure accurately discriminates susceptible, intermediate and resistant strains of Escherichia coli to amoxicillin/clavulanic acid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21867549", "endSection": "abstract"}, {"offsetInBeginSection": 1047, "offsetInEndSection": 1255, "text": "Surprisingly, also cinnamycin of Streptomyces cinnamoneus cinnamoneus), previously known to bind specifically to phosphatidylethanolamin of biological membranes, provoked strong cell wall biosynthetic stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18558445", "endSection": "abstract"}, {"offsetInBeginSection": 571, "offsetInEndSection": 727, "text": "Here, we compare the staining patterns observed in Bacillus subtilis using fluorescent derivatives of two PG-binding antibiotics, vancomycin and ramoplanin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16832063", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1061, "text": "Ramoplanin probes may be better imaging agents than vancomycin probes because they yield clear staining patterns at concentrations well below their minimum inhibitory concentrations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16832063", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12197711", "endSection": "title"}, {"offsetInBeginSection": 315, "offsetInEndSection": 605, "text": "The muraymycins constitute a new antibiotic family whose core structure contains a glycosylated uronic acid derivative joined by an aminopropane group to a hexahydro-2-imino-4-pyrimidylglycyl residue (epicapreomycidine) containing dipeptide that is further extended by a urea-valine moiety.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12197711", "endSection": "abstract"}, {"offsetInBeginSection": 742, "offsetInEndSection": 796, "text": "The muraymycins inhibited peptidoglycan biosynthesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12197711", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan biosynthesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12440876", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Ramoplanin is a cyclicdepsipeptide antibiotic that inhibits peptidoglycan biosynthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12440876", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Vancomycin binds to bacterial cell-wall intermediates to achieve its antibiotic effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10801476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9210483", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "The lantibiotic mersacidin has been previously reported to interfere with bacterial peptidoglycan biosynthesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9210483", "endSection": "abstract"}, {"offsetInBeginSection": 225, "offsetInEndSection": 454, "text": "Here, we focus on the target reaction and describe a mersacidin-induced accumulation of UDP-N-acetylmuramoyl-pentapeptide, indicating that inhibition of peptidoglycan synthesis occurs after the formation of cytoplasmic precursors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9210483", "endSection": "abstract"}, {"offsetInBeginSection": 1099, "offsetInEndSection": 1430, "text": "The analogy to the glycopeptides may hint at an interaction of mersacidin with the peptidoglycan precursor rather than with the enzyme. Unlike vancomycin however, mersacidin inhibits peptidoglycan formation from UDP-N-acetylmuramoyl-tripeptide and is active against Enterococcus faecium expressing the vanA resistance gene cluster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9210483", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8891144", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 449, "text": "LY191145 is a p-chlorobenzyl derivative of LY264826 (A82846B) with activity against both vancomycin-susceptible and -resistant enterococci. Incorporation of L-[14C]lysine into peptidoglycan of intact vancomycin-susceptible and -resistant Enterococcus faecium was inhibited by LY191145 (50% inhibitory concentrations of 1 and 5 microgram/ml, respectively). Inhibition was accompanied by accumulation of UDP-muramyl-peptide precursors in the cytoplasm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8891144", "endSection": "abstract"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1397, "text": "The fact that inhibition of peptidoglycan biosynthesis by LY191145 was not readily antagonized by an excess of free acyl-D-alanyl-D-alanine or acyl-D-alanyl-D-lactate ligands indicates that the manner in which this compound inhibits transglycosylation may not be identical to that of vancomycin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8891144", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 980, "text": "Comparison with tunicamycin-treated cells indicated that peptidoglycan rather than teichoic acid metabolism is primarily affected", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "endSection": "abstract"}, {"offsetInBeginSection": 982, "offsetInEndSection": 1076, "text": "Mersacidin caused the excretion of a putative cell wall precursor into the culture supernatant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 267, "text": "Mersacidin is an antibiotic peptide produced by Bacillus sp. strain HIL Y-85,54728 that belongs to the group of lantibiotics. Its activity in vivo against methicillin-resistant Staphylococcus aureus strains compares with that of the glycopeptide antibiotic vancomycin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "endSection": "abstract"}, {"offsetInBeginSection": 413, "offsetInEndSection": 521, "text": "Incubation of Staphylococcus simulans 22 with mersacidin resulted in the cessation of growth and slow lysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "endSection": "abstract"}, {"offsetInBeginSection": 1213, "offsetInEndSection": 1437, "text": "n contrast to vancomycin, the activity of mersacidin was not antagonized by the tripeptide diacetyl-L-Lys-D-Ala-D-Ala, indicating that on the molecular level its mode of action differs from those of glycopeptide antibiotics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7793878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Inhibition of peptidoglycan biosynthesis by ramoplanin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2334153", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Ramoplanin, a new lipoglycopeptide antibiotic, inhibits cell wall peptidoglycan biosynthesis in gram-positive bacteria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2334153", "endSection": "abstract"}]}, {"body": "Which protein does empagliflozin inhibit?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26045645"], "ideal_answer": ["Empagliflozin (Jardiance)  is a SGLT2 inhibitor."], "exact_answer": [["SGLT2"]], "type": "factoid", "id": "571e12097de986d80d000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045645", "endSection": "abstract"}]}, {"body": "Is glycyl-tRNA synthetase gene involved in the development of Charcot-Marie-Tooth disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25168514", "http://www.ncbi.nlm.nih.gov/pubmed/24669931", "http://www.ncbi.nlm.nih.gov/pubmed/24898252", "http://www.ncbi.nlm.nih.gov/pubmed/24368416", "http://www.ncbi.nlm.nih.gov/pubmed/25420567"], "ideal_answer": ["Dominant mutations in GARS, encoding the essential enzyme glycyl-tRNA synthetase (GlyRS), result in a form of Charcot-Marie-Tooth disease, type 2D (CMT2D), predominantly characterized by lower motor nerve degeneration.", "Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D", "Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D", "Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D", "Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D", "Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D"], "exact_answer": "yes", "type": "yesno", "id": "5713c4a11174fb1755000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "Charcot-Marie-Tooth disease type 2D (CMT2D) is an autosomal-dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl-tRNA synthetase (GARS) gene cause CMT2D", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25168514", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 375, "text": "Dominant mutations in GARS cause rare forms of Charcot-Marie-Tooth disease and distal spinal muscular atrophy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669931", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 809, "text": "Using exome sequencing she was found to harbor compound heterozygous mutations within the glycyl-tRNA synthetase (GARS) gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669931", "endSection": "abstract"}, {"offsetInBeginSection": 329, "offsetInEndSection": 428, "text": "mutations of human GlyRS (hGlyRS) were also found to be associated with Charcot-Marie-Tooth disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24898252", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Dominant mutations in GARS, encoding the essential enzyme glycyl-tRNA synthetase (GlyRS), result in a form of Charcot-Marie-Tooth disease, type 2D (CMT2D), predominantly characterized by lower motor nerve degeneration", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24368416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "A novel mutation in glycyl-tRNA synthetase caused Charcot-Marie-Tooth disease type 2D with facial and respiratory muscle involvement", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25420567", "endSection": "title"}, {"offsetInBeginSection": 342, "offsetInEndSection": 957, "text": "Here we describe a 45-year-old woman with a long course of motor-dominant neuropathy. Distal weakness appeared in childhood and became worse with age. After a diagnosis of CMT type 2, the symptoms progressed, and in her fourth decade, facial and respiratory muscle weakness appeared, ultimately requiring non-invasive mechanical ventilation. There was no family history of CMT. Comprehensive analysis of known CMT-related genes revealed a novel heterozygous c.815T>A, p.L218Q mutation in glycyl-tRNA synthetase (GARS), a causative gene for both CMT type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25420567", "endSection": "abstract"}]}, {"body": "Which bacteria caused plague?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16410352", "http://www.ncbi.nlm.nih.gov/pubmed/8052312"], "ideal_answer": ["Yersinia pestis is the causative bacteria of the plague."], "exact_answer": [["Yersinia pestis"]], "type": "factoid", "id": "571cdd227de986d80d00000f", "snippets": [{"offsetInBeginSection": 187, "offsetInEndSection": 344, "text": " the causative bacteria Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16410352", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 256, "text": "Yersinia, the causative bacteria of the bubonic plague and other enteric diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8052312", "endSection": "abstract"}]}, {"body": "Why can't humans synthesize Neu5Gc (N-Glycolylneuraminic acid)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24505439", "http://www.ncbi.nlm.nih.gov/pubmed/25003133", "http://www.ncbi.nlm.nih.gov/pubmed/25124893", "http://www.ncbi.nlm.nih.gov/pubmed/23520510", "http://www.ncbi.nlm.nih.gov/pubmed/22390546", "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "http://www.ncbi.nlm.nih.gov/pubmed/16806174"], "ideal_answer": ["N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. Losing this sugar changed how humans interact with some of our deadliest pathogens: malaria, influenza, and streptococcus among others."], "type": "summary", "id": "57152ebbcb4ef8864c000002", "snippets": [{"offsetInBeginSection": 755, "offsetInEndSection": 1008, "text": "Human muscle from normal (no evident disease, n\u200a=\u200a3), Becker (BMD, n\u200a=\u200a3) and Duchenne (DMD, n\u200a=\u200a3) muscular dystrophy individuals had absent to very low Neu5Gc staining, but some punctate intracellular muscle staining was present in BMD and DMD muscles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24505439", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 115, "text": "N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25003133", "endSection": "abstract"}, {"offsetInBeginSection": 77, "offsetInEndSection": 387, "text": "Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. Losing this sugar changed how humans interact with some of our deadliest pathogens: malaria, influenza, and streptococcus among others.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124893", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 399, "text": "Anti-Neu5Gc antibodies are detected in all human sera, though with variable levels and epitope-recognition profiles. These antibodies likely play a role in several inflammation-mediated pathologies including cardiovascular diseases and cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23520510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Human polyclonal IgG antibodies directly against the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc) are potential biomarkers and mechanistic contributors to cancer and other diseases associated with chronic inflammation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Human heterophile antibodies that agglutinate animal erythrocytes are known to detect the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Nonhuman sialic acid Neu5Gc is very low in human embryonic stem cell-derived neural precursors differentiated with B27/N2 and noggin", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806174", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "A concern recently has been raised that human embryonic stem cell (HESC) lines cultured with currently available methods may have limited clinical usefulness due to the immunogenicity of the nonhuman sialic acid Neu5Gc incorporated into their membranes during culturing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806174", "endSection": "abstract"}]}, {"body": "For which type of diabetes can empagliflozin be used?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25712444"], "ideal_answer": ["The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM."], "exact_answer": [["type 2 diabetes mellitus"]], "type": "factoid", "id": "571e14fbbb137a4b0c000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", "endSection": "title"}, {"offsetInBeginSection": 11, "offsetInEndSection": 257, "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", "endSection": "abstract"}]}, {"body": "Have C12orf65 mutations been associated with axonal neuropathy and optic atrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24198383"], "ideal_answer": ["The association of neuropathy and optic atrophy (also known as Charcot-Marie-Tooth [CMT] disease type 6) has been described with autosomal dominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, whereas a protein-truncating mutation in the C12orf65 gene, which codes for a protein involved in mitochondrial translation, was found to be the cause of an autosomal recessive form of the disease, with childhood onset neuropathy and optic atrophy.", "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy", "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy", "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy", "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy", "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy"], "exact_answer": "yes", "type": "yesno", "id": "5713c7dd1174fb1755000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383", "endSection": "title"}, {"offsetInBeginSection": 11, "offsetInEndSection": 1031, "text": "Charcot-Marie Tooth disease (CMT) forms a clinically and genetically heterogeneous group of disorders. Although a number of disease genes have been identified for CMT, the gene discovery for some complex form of CMT has lagged behind. The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but until now, mutations in the recessive forms of disease have never been identified.METHODS: We here describe a family with three affected individuals who inherited in an autosomal recessive fashion a childhood onset neuropathy and optic atrophy. Using homozygosity mapping in the family and exome sequencing in two affected individuals we identified a novel protein-truncating mutation in the C12orf65 gene, which encodes for a protein involved in mitochondrial translation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383", "endSection": "abstract"}]}, {"body": "In which cells are gasdermins expressed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18693275", "http://www.ncbi.nlm.nih.gov/pubmed/23979942", "http://www.ncbi.nlm.nih.gov/pubmed/19051310", "http://www.ncbi.nlm.nih.gov/pubmed/15737203"], "ideal_answer": ["Members of the novel gene family Gasdermin (Gsdm) are exclusively expressed in a highly tissue-specific manner in the epithelium of skin and the gastrointestinal tract."], "exact_answer": [["epithelial cells"]], "type": "factoid", "id": "571ce13f7de986d80d000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Members of the novel gene family Gasdermin (Gsdm) are exclusively expressed in a highly tissue-specific manner in the epithelium of skin and the gastrointestinal tract. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18693275", "endSection": "abstract"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1382, "text": "These results indicate that the mouse Gsdma and Gsdma3 genes share common function to regulate epithelial maintenance ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979942", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Gasdermin (GSDM or GSDMA), expressed in the upper gastrointestinal tract but frequently silenced in gastric cancers (GCs), regulates apoptosis of the gastric epithelium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19051310", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 1294, "text": ". Immunohistochemical analysis revealed that gasdermins are expressed specifically in cells at advanced stages of differentiation in the upper epidermis, the differentiating inner root sheath and hair shaft and in the most mature sebocytes of the sebaceous gland and preputial, meibomium, ceruminous gland, and anal glands. This expression pattern suggests a role for gasdermins in differentiation of the epidermis and its appendages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15737203", "endSection": "abstract"}]}, {"body": "Which are the most common methods for ctDNA (circulating tumour DNA) detection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26539452", "http://www.ncbi.nlm.nih.gov/pubmed/25220802", "http://www.ncbi.nlm.nih.gov/pubmed/25489581", "http://www.ncbi.nlm.nih.gov/pubmed/24705333", "http://www.ncbi.nlm.nih.gov/pubmed/20970979"], "ideal_answer": ["Recently, nanoplasmonics has emerged as a platform for one-step dual detection with high sensitivity and specificity. The practice of \"liquid biopsy\" as a diagnostic, prognostic and theranostic tool in non-small cell lung cancer (NSCLC) patients is an appealing approach, at least in theory, since it is noninvasive and easily repeated. Cancer personalized profiling by deep sequencing (CAPP-Seq), an economical and ultrasensitive method for quantifying ctDNA. A new DNA sensor using a nickel(II) phenanthroline complex ([Ni(phen)(2)PHPIP]\u00b72ClO(4)) as the electrochemical probe was developed. The sensor is very sensitive and selective for calf thymus DNA (ctDNA) detection in aqueous medium.", "A new DNA sensor using a nickel(II) phenanthroline complex ([Ni(phen)(2)PHPIP]\u00b72ClO(4)) as the electrochemical probe was developed. The calculated dynamics parameters of the electrode process indicate that there are obvious interactions between the probe and the ctDNA in aqueous solution. Under constant potential conditions, the redox current peak of the probe (Ni-complex) decreases obviously as the probe interacts/binds with ctDNAs. These results demonstrate that the sensor can simultaneously detect the hot-spot mutation and epigenetic changes on the ctDNA."], "exact_answer": [["nanoplasmonics", "biosensors"], ["liquid biopsy"], ["Cancer personalized profiling by deep sequencing", "CAPP-Seq"], ["electrochemical sensors"]], "type": "list", "id": "571653aecb4ef8864c000005", "snippets": [{"offsetInBeginSection": 147, "offsetInEndSection": 220, "text": "existing methods for ctDNA detection are restricted to genetic mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220802", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 338, "text": "Recently, nanoplasmonics has emerged as a platform for one-step dual detection with high sensitivity and specificity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220802", "endSection": "abstract"}, {"offsetInBeginSection": 1250, "offsetInEndSection": 1498, "text": "These results demonstrate that the sensor can simultaneously detect the hot-spot mutation and epigenetic changes on the ctDNA. Promisingly, other specific-tumor mutants and epigenetic changes can be detected at low concentration with this platform.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220802", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "The practice of \"liquid biopsy\" as a diagnostic, prognostic and theranostic tool in non-small cell lung cancer (NSCLC) patients is an appealing approach, at least in theory, since it is noninvasive and easily repeated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25489581", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 363, "text": "Here we introduce cancer personalized profiling by deep sequencing (CAPP-Seq), an economical and ultrasensitive method for quantifying ctDNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24705333", "endSection": "abstract"}, {"offsetInBeginSection": 937, "offsetInEndSection": 1171, "text": "Finally, we evaluated biopsy-free tumor screening and genotyping with CAPP-Seq. We envision that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24705333", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Synthesis of a new Ni-phenanthroline complex and its application as an electrochemical probe for detection of nucleic acid", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20970979", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "A new DNA sensor using a nickel(II) phenanthroline complex ([Ni(phen)(2)PHPIP]\u00b72ClO(4)) as the electrochemical probe was developed. The sensor is very sensitive and selective for calf thymus DNA (ctDNA) detection in aqueous medium. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20970979", "endSection": "abstract"}]}, {"body": "When was empagliflozin FDA approved?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25712444"], "ideal_answer": ["Empagliflozin was approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM)."], "exact_answer": [["2014"]], "type": "factoid", "id": "571e172bbb137a4b0c000002", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 257, "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", "endSection": "abstract"}]}, {"body": "Which peripheral neuropathy has been associated with NDRG1 mutations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21303696", "http://www.ncbi.nlm.nih.gov/pubmed/12872253"], "ideal_answer": ["Charcot-Marie-Tooth (CMT) 4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1).", "CMT4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1)", "CMT4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1)", "CMT4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1)", "CMT4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1)", "CMT4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1)"], "exact_answer": [["Charcot-Marie-Tooth (CMT) 4D disease"]], "type": "factoid", "id": "5713c8d71174fb1755000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "CMT4D disease is a severe autosomal recessive demyelinating neuropathy with extensive axonal loss leading to early disability, caused by mutations in the N-myc downstream regulated gene 1 (NDRG1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303696", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "In a previous study, we have shown that N-myc downstream-regulated gene 1 (NDRG1), classified in databases as a tumor suppressor and heavy metal-response protein, is mutated in hereditary motor and sensory neuropathy Lom (HMSNL), a severe autosomal recessive form of Charcot-Marie-Tooth (CMT) disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12872253", "endSection": "abstract"}]}, {"body": "What is the function of 6SRNA in bacteria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22214309", "http://www.ncbi.nlm.nih.gov/pubmed/17332013", "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "http://www.ncbi.nlm.nih.gov/pubmed/2579060", "http://www.ncbi.nlm.nih.gov/pubmed/58611"], "ideal_answer": ["Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. 6S RNA-deficient cells are at a disadvantage for survival in stationary phase, a time when 6S RNA regulates transcription. 6S RNA regulation of both sigma(70) and sigma(S) activities contributes to increased cell persistence during nutrient deprivation. 6S RNA acts as a template for the transcription of defined RNA molecules in the absence of DNA. 6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase.", "6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase. Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. The carboxy terminus containing the Arg-Gly-Gly (RGG) repeat domains in these proteins are necessary for cis-repression of transcription activation and HAT activity by the N-terminal glutamine-rich domain.", "6S RNA function enhances long-term cell survival. "], "type": "summary", "id": "57169662cb4ef8864c000008", "snippets": [{"offsetInBeginSection": 464, "offsetInEndSection": 643, "text": "Qbeta replicase lacking subunit alpha (R-alpha) is capable of replicating templates other than (+) strand, such as (--), \"6S\" RNA, poly(C) etc., in the absence of the host factor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/58611", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Escherichia coli 6S RNA gene is part of a dual-function transcription unit.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2579060", "endSection": "title"}, {"offsetInBeginSection": 152, "offsetInEndSection": 697, "text": "The DNA sequence results confirm the accuracy of the previously established RNA sequence and, with genomic hybridization data, reveal that there is only one copy of the 6S DNA in the chromosome. Consistent with its relaxed mode of expression, the promoter region of the 6S RNA gene was found to lack the hypothetical GC-rich discriminator domain common to other stable RNA genes under stringent control. The sequence results also revealed the occurrence of a 540-base-pair open reading frame immediately downstream from the 6S RNA coding region.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2579060", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "6S RNA function enhances long-term cell survival.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "endSection": "title"}, {"offsetInBeginSection": 143, "offsetInEndSection": 265, "text": "6S RNA-deficient cells are at a disadvantage for survival in stationary phase, a time when 6S RNA regulates transcription.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "endSection": "abstract"}, {"offsetInBeginSection": 495, "offsetInEndSection": 685, "text": "6S RNA inhibition of sigma(70)-dependent transcription was not ubiquitous, in spite of the fact that the vast majority of sigma(70)-RNA polymerase is bound by 6S RNA during stationary phase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "endSection": "abstract"}, {"offsetInBeginSection": 686, "offsetInEndSection": 856, "text": "The sigma(70)-dependent promoters inhibited by 6S RNA contain an extended -10 promoter element, suggesting that this feature may define a class of 6S RNA-regulated genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "endSection": "abstract"}, {"offsetInBeginSection": 875, "offsetInEndSection": 980, "text": " a secondary effect of 6S RNA in the activation of sigma(S)-dependent transcription at several promoters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "endSection": "abstract"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1128, "text": "6S RNA regulation of both sigma(70) and sigma(S) activities contributes to increased cell persistence during nutrient deprivation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262935", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Escherichia coli 6S RNA represents a non-coding RNA (ncRNA), which, based on the conserved secondary structure and previous functional studies, had been suggested to interfere with transcription. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17332013", "endSection": "abstract"}, {"offsetInBeginSection": 590, "offsetInEndSection": 702, "text": "Preferred binding of 6S RNA to Esigma(70) was confirmed, however weaker binding to Esigma(38) was also observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17332013", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1355, "text": "Moreover, we show for the first time that 6S RNA acts as a template for the transcription of defined RNA molecules in the absence of DNA. In conclusion, this study reveals new aspects of 6S RNA function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17332013", "endSection": "abstract"}, {"offsetInBeginSection": 293, "offsetInEndSection": 501, "text": "6S RNA, first described as a ncRNA in E. coli, mimics an open promoter structure, which has a large bulge with two hairpin/stalk structures that regulate transcription through interactions with RNA polymerase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22214309", "endSection": "abstract"}]}, {"body": "List sodium glucose co-transporter-2 (SGLT2) inhibitors that have been FDA approved for type 2 diabetes mellitus treatment.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24998153", "http://www.ncbi.nlm.nih.gov/pubmed/25712444"], "ideal_answer": ["Canagliflozin, along with dapagliflozin and empagliflozin, are SGLT2 inhibitors approved by the US FDA for use in the treatment of type 2 diabetes."], "exact_answer": [["Dapagliflozin"], ["Empagliflozin"], ["Canagliflozin"]], "type": "list", "id": "571e189dbb137a4b0c000003", "snippets": [{"offsetInBeginSection": 151, "offsetInEndSection": 319, "text": "Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24998153", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 257, "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", "endSection": "abstract"}, {"offsetInBeginSection": 656, "offsetInEndSection": 802, "text": " Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", "endSection": "abstract"}]}, {"body": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24458521"], "ideal_answer": ["Compared to age-matched controls, fibronectin levels in DMD patients were found to be significantly increased, whereas in patients with Becker muscular dystrophy, Bethlem myopathy, or myasthenia gravis were close to the control levels. Additionally, progressive elevation in fibronectin levels was observed in longitudinal samples from DMD patients followed up for a period of 6 months up to 4 years. Therefore, fibronectin is a serum biomarker for Duchenne muscular dystrophy.", "Fibronectin is a serum biomarker for Duchenne muscular dystrophy", "Fibronectin is a serum biomarker for Duchenne muscular dystrophy", "Fibronectin is a serum biomarker for Duchenne muscular dystrophy", "Fibronectin is a serum biomarker for Duchenne muscular dystrophy", "Fibronectin is a serum biomarker for Duchenne muscular dystrophy"], "exact_answer": "yes", "type": "yesno", "id": "5715c16dcb4ef8864c000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Fibronectin is a serum biomarker for Duchenne muscular dystrophy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521", "endSection": "title"}, {"offsetInBeginSection": 792, "offsetInEndSection": 1186, "text": "There was a significant increase in fibronectin levels in DMD patients compared to age-matched controls. Fibronectin levels in patients with Becker muscular dystrophy, Bethlem myopathy, or myasthenia gravis were comparable to control levels. Progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521", "endSection": "abstract"}, {"offsetInBeginSection": 1222, "offsetInEndSection": 1355, "text": "This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521", "endSection": "abstract"}]}, {"body": "Can RNAPolII function as an RNA-dependent RNA-polymerase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23395899", "http://www.ncbi.nlm.nih.gov/pubmed/18004386", "http://www.ncbi.nlm.nih.gov/pubmed/15827195", "http://www.ncbi.nlm.nih.gov/pubmed/17132145", "http://www.ncbi.nlm.nih.gov/pubmed/16624367"], "ideal_answer": ["RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity. Pol II can use a homopolymeric RNA template, can extend RNA by several nucleotides in the absence of DNA, and has been implicated in the replication of the RNA genomes of hepatitis delta virus (HDV) and plant viroids. The RdRP activity of Pol II provides a missing link in molecular evolution, because it suggests that Pol II evolved from an ancient replicase that duplicated RNA genomes.", "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA", "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA", "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA", "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA", "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA", "There is, however, evidence that Pol II also possesses RNA-dependent RNA polymerase (RdRP) activity. Here we show the intrinsic RdRP activity of Pol II with only pure polymerase, an RNA template-product scaffold and nucleoside triphosphates (NTPs). RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity. We conclude that influenza A virus replication requires RNAP-II activity not just to provide capped mRNA substrates but also to facilitate nuclear export of selected viral mRNAs."], "exact_answer": "yes", "type": "yesno", "id": "571696d9cb4ef8864c000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "RNA polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "RNA polymerase II (Pol II) is a well-characterized DNA-dependent RNA polymerase, which has also been reported to have RNA-dependent RNA polymerase (RdRP) activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 913, "text": ". Our studies provide compelling evidence that mammalian Pol II acts as an RdRP to control the stability of a cellular RNA by extending its 3'-end.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395899", "endSection": "abstract"}, {"offsetInBeginSection": 90, "offsetInEndSection": 407, "text": "here is, however, evidence that Pol II also possesses RNA-dependent RNA polymerase (RdRP) activity. Pol II can use a homopolymeric RNA template, can extend RNA by several nucleotides in the absence of DNA, and has been implicated in the replication of the RNA genomes of hepatitis delta virus (HDV) and plant viroids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18004386", "endSection": "abstract"}, {"offsetInBeginSection": 1171, "offsetInEndSection": 1341, "text": "The RdRP activity of Pol II provides a missing link in molecular evolution, because it suggests that Pol II evolved from an ancient replicase that duplicated RNA genomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18004386", "endSection": "abstract"}, {"offsetInBeginSection": 793, "offsetInEndSection": 1017, "text": "The present findings provide a framework for further studies to elucidate the mechanistic principles of transcription by a viral RNA polymerase and have implications for the regulation of Pol II activities in infected cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Influenza A virus transcribes its segmented negative sense RNA genome in the nuclei of infected cells in a process long known to require host RNA polymerase II (RNAP-II).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17132145", "endSection": "abstract"}, {"offsetInBeginSection": 1207, "offsetInEndSection": 1385, "text": "We conclude that influenza A virus replication requires RNAP-II activity not just to provide capped mRNA substrates but also to facilitate nuclear export of selected viral mRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17132145", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 985, "text": "Thus, influenza virus specifically interferes with Pol II elongation, but not Pol II initiation. We propose that influenza virus RNA polymerase, by binding to the CTD of initiating Pol II and subsequent cleavage of the capped 5' end of the nascent transcript, triggers premature Pol II termination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16624367", "endSection": "abstract"}]}, {"body": "List side effects of SGLT2 inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23807940", "http://www.ncbi.nlm.nih.gov/pubmed/24825435"], "ideal_answer": ["SGLT2 inhibitors can be associated with urogenital infections related to the enhanced glycosuria, and low blood pressure."], "exact_answer": [["urinary tract infections"], ["genital infections"], ["low blood pressure"]], "type": "list", "id": "571e1e11bb137a4b0c000004", "snippets": [{"offsetInBeginSection": 515, "offsetInEndSection": 697, "text": "Due to side effects such as urinary tract and genital infections and decrease in blood pressure, proper patient selection for drug initiation and close monitoring will be important. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23807940", "endSection": "abstract"}, {"offsetInBeginSection": 1618, "offsetInEndSection": 1732, "text": "Urogenital side-effects related to the enhanced glycosuria can be troublesome, yet seldom lead to discontinuation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825435", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 1019, "text": "Promotion of urinary loss of glucose by SGLT2 inhibitors embodies a new principle of control in type 2 diabetes that has several advantages with some urogenital side-effects, both of which are evaluated in this review. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825435", "endSection": "abstract"}]}, {"body": "Which is the mechanism used for synthesis of a highly functional N-truncated dystrophin isoform that attenuates dystrophinopathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25108525"], "ideal_answer": ["Alternative translation initiation beginning in DMD exon 6 with the use of an internal ribosome entry site (IRES) within exon 5 that is glucocorticoid inducible leads to expression of a highly functional N-truncated dystrophin isoform which is able to ameliorate disease severity.", "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice", "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice", "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice", "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice", "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice", "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice "], "type": "summary", "id": "57167625cb4ef8864c000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108525", "endSection": "title"}, {"offsetInBeginSection": 149, "offsetInEndSection": 488, "text": "amelioration of disease severity has been shown to result from alternative translation initiation beginning in DMD exon 6 that leads to expression of a highly functional N-truncated dystrophin. Here we demonstrate that this isoform results from usage of an internal ribosome entry site (IRES) within exon 5 that is glucocorticoid inducible", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108525", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of decitabine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25130173", "http://www.ncbi.nlm.nih.gov/pubmed/22893792", "http://www.ncbi.nlm.nih.gov/pubmed/16043219"], "ideal_answer": ["Decitabine is a potent demethylating agent that exhibits clinical activity against myeloid malignancies. Numerous genes silenced by hypermethylation are reactivated by decitabine through a mechanism involving promoter demethylation with subsequent release of histone deacetylases (HDACs) and accumulation of acetylated histones. Recent studies indicating that decitabine also induces regional chromatin remodeling of some unmethylated genes suggest additional mechanisms of action.", "The use of the DNA methylation inhibitor decitabine (Dacogen\u00ae) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention.", "The use of the DNA methylation inhibitor decitabine (Dacogen\u00ae) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention.", "The use of the DNA methylation inhibitor decitabine (Dacogen\u00ae) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention.", "The use of the DNA methylation inhibitor decitabine (Dacogen\u00ae) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention.", "The use of the DNA methylation inhibitor decitabine (Dacogen\u00ae) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention.", "Decitabine reactivates unmethylated p21WAF1 in some AML cell lines but the possible occurrence of p21WAF1 methylation in AML in vivo has not been studied in detail and decitabine effects on p21WAF1 chromatin remodeling have not been reported. We also discuss the following questions: What is the best administration schedule of decitabine in solid tumors? Is there tumor type specificity for decitabine-based epigenetic therapy? We found that p21WAF1 mRNA was undetectable in 6 of 24 AML patient samples and 4 of 5 AML cell lines but there was no evidence of p21WAF1 promoter methylation."], "type": "summary", "id": "57169a49cb4ef8864c00000a", "snippets": [{"offsetInBeginSection": 92, "offsetInEndSection": 284, "text": "The use of the DNA methylation inhibitor decitabine (Dacogen\u00ae) has been approved in the treatment of hematological malignancies, and its clinical effects on solid tumors have gained attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25130173", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 913, "text": "low-dose decitabine and combined therapy show significant improvement in solid tumor treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25130173", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 405, "text": "Here, we demonstrate dose-dependent degradation of Dnmt1 in mouse embryonic stem (ES) cells expressing catalytic site mutant (cys-ser), confirming that the covalent bond formation between Dnmt1 and decitabine-incorporated DNA is not essential for this process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893792", "endSection": "abstract"}, {"offsetInBeginSection": 407, "offsetInEndSection": 633, "text": "NMT1o, the oocyte-specific isoform that lacks the N-terminal 118-amino acid domain, did not undergo decitabine-mediated degradation, which further proves the requirement of multiple domains including nuclear localization signa", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893792", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 859, "text": "Analysis of glycerol density gradient fractions of micrococcal nuclease-digested nuclei showed that both nucleosomal and nucleoplasmic DNMT1 are degraded upon decitabine treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893792", "endSection": "abstract"}, {"offsetInBeginSection": 1011, "offsetInEndSection": 1161, "text": "The maximal effect caused by inhibiting protein kinase C (PKC) persuaded us to investigate further its role in decitabine-mediated DNMT1 degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893792", "endSection": "abstract"}, {"offsetInBeginSection": 1530, "offsetInEndSection": 1766, "text": "These studies provide substantial evidence that decitabine-induced degradation of the maintenance methyltransferase DNMT1 does not require covalent bond formation with the substrate and also elucidate its underlying molecular mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 481, "text": "Decitabine is a potent demethylating agent that exhibits clinical activity against myeloid malignancies. Numerous genes silenced by hypermethylation are reactivated by decitabine through a mechanism involving promoter demethylation with subsequent release of histone deacetylases (HDACs) and accumulation of acetylated histones. Recent studies indicating that decitabine also induces regional chromatin remodeling of some unmethylated genes suggest additional mechanisms of action.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16043219", "endSection": "abstract"}]}, {"body": "What are 'vildagliptin', 'sitagliptin', 'saxagliptin', 'alogliptin', 'linagliptin', and 'dutogliptin'?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22215383"], "ideal_answer": ["\"Sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and \"dutogliptin\" are dipeptidyl peptidase-4 (DPP-4) inhibitors."], "exact_answer": [["dipeptidyl peptidase-4 (DPP-4) inhibitors"]], "type": "factoid", "id": "571e275dbb137a4b0c000005", "snippets": [{"offsetInBeginSection": 301, "offsetInEndSection": 785, "text": "The present metaanalysis was designed to assess the effect of DPP-4 inhibitors on blood lipids, verifying possible differences across compounds of this class.METHODS: An extensive search of Medline and the Cochrane Library (any date up to December 31, 2010, restricted to randomized clinical trials, published in English) was performed for all trials containing, in any field, the words \"sitagliptin,\" \"vildagliptin,\" \"saxagliptin,\" \"alogliptin,\" \"linagliptin,\" and/or \"dutogliptin.\" ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22215383", "endSection": "abstract"}]}, {"body": "Which are the main functions of G3BP1 and G3BP2 proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24992036", "http://www.ncbi.nlm.nih.gov/pubmed/23279204", "http://www.ncbi.nlm.nih.gov/pubmed/24321297", "http://www.ncbi.nlm.nih.gov/pubmed/22703643", "http://www.ncbi.nlm.nih.gov/pubmed/20392851", "http://www.ncbi.nlm.nih.gov/pubmed/17297477"], "ideal_answer": ["The main functions of G3BP1 and/or G3BP2 include translation of interferon stimulated mRNAs during dengue virus infection, initiation of assembly of stress granules, regulation of PMP22 mRNA which was found to affect cell proliferation in breast cancer cells, participation in several signaling pathways involved in growth, differentiation and apoptosis in human tumor cells after overexpression, limit viral replication events during Sindbis virus (SINV) infection, and modulation of p53 and MDM2 activity."], "exact_answer": [["Translation of interferon stimulated mRNAs during dengue virus infection"], ["Initiation of assembly of stress granules"], ["Regulation of PMP22 mRNA which was found to affect cell proliferation in breast cancer cells"], ["Participation in several signaling pathways involved in growth, differentiation and apoptosis in human tumor cells after overexpression"], ["Limit viral replication events during Sindbis virus (SINV) infection"], ["Modulation of p53 and MDM2 activity"]], "type": "list", "id": "5717ab7ccb4ef8864c00000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Both G3BP1 and G3BP2 contribute to stress granule formation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279204", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "G3BP1, G3BP2 and CAPRIN1 are required for translation of interferon stimulated mRNAs and are targeted by a dengue virus non-coding RNA", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992036", "endSection": "title"}, {"offsetInBeginSection": 200, "offsetInEndSection": 406, "text": "We examined three conserved host RNA-binding proteins (RBPs) G3BP1, G3BP2 and CAPRIN1 in dengue virus (DENV-2) infection and found them to be novel regulators of the interferon (IFN) response against DENV-2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992036", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 675, "text": "Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) is a component of SGs that initiates the assembly of SGs by forming a multimer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279204", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 964, "text": "Although single knockdown of either G3BP1 or G3BP2 in 293T cells partially reduced the number of SG-positive cells induced by arsenite, the knockdowns of both genes significantly reduced the number", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279204", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1118, "text": "like G3BP1, the overexpression of G3BP2 induced SGs even without stress stimuli", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279204", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1290, "text": "Collectively, these results suggest that both G3BP1 and G3BP2 play a role in the formation of SGs in various human cells and thereby recovery from these cellular stresses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279204", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Regulation of PMP22 mRNA by G3BP1 affects cell proliferation in breast cancer cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321297", "endSection": "title"}, {"offsetInBeginSection": 298, "offsetInEndSection": 379, "text": "G3BP has been reported to both stabilize and induce degradation of specific mRNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321297", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 791, "text": "Global gene expression analyses of G3BP1- and G3BP2-depleted cells indicate that primarily G3BP1, and much less G3BP2, influences mRNA expression levels. Peripheral myelin protein 22 (PMP22) was one gene that was significantly influenced by G3BP1 depletion which led to a 2-3 fold increased expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321297", "endSection": "abstract"}, {"offsetInBeginSection": 793, "offsetInEndSection": 928, "text": "Depletion of PMP22 resulted in increased proliferation and the G3BP1-mediated effect on proliferation was not seen upon PMP22-depletion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321297", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Ras-GTPase-activating protein SH3 domain-binding proteins (G3BP) are overexpressed in various human tumors and participate in several signaling pathways involved in growth, differentiation and apoptosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703643", "endSection": "abstract"}, {"offsetInBeginSection": 894, "offsetInEndSection": 1219, "text": "Two related proteins found in association with nsP4 at both times of infection, GTPase-activating protein (SH3 domain) binding protein 1 (G3BP1) and G3BP2 were also previously identified as associated with SINV nsP2 and nsP3. We demonstrate a likely overlapping role for these host factors in limiting SINV replication events", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392851", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17297477", "endSection": "title"}, {"offsetInBeginSection": 308, "offsetInEndSection": 922, "text": "we have found that members of the Ras network of proteins, Ras-GTPase activating protein-SH3-domain-binding proteins 1 and 2 (G3BP1 and 2), bind to p53 in vitro and in vivo. Our data show that expression of G3BPs leads to the redistribution of p53 from the nucleus to the cytoplasm. The G3BP2 isoform additionally associated with murine double minute 2 (MDM2), a negative regulator of p53. G3BP2 expression resulted in significant reduction in MDM2-mediated p53 ubiquitylation and degradation. Interestingly, MDM2 was also stabilized in G3BP2-expressing cells and its ability to ubiquitylate itself was compromised", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17297477", "endSection": "abstract"}]}, {"body": "Which are the human glutamate transporters?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22539860", "http://www.ncbi.nlm.nih.gov/pubmed/14672993", "http://www.ncbi.nlm.nih.gov/pubmed/18096700", "http://www.ncbi.nlm.nih.gov/pubmed/15863236"], "ideal_answer": ["Glutamate/aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) are the most abundant subtypes and are essential for the functioning of the mammalian CNS, but the contribution of the EAAC1 subtype in the clearance of synaptic glutamate has remained controversial, because the density of this transporter in different tissues has not been determined. Using immunofluorescence and postembedding immunogold labeling, we investigated the distributions of the glutamate-aspartate transporter (GLAST or excitatory amino acid transporter 1), vesicular glutamate transporter (VGLUT1), and the AMPA receptor glutamate receptor 4 (GluR4) along the spiral.", "To date, five distinct mammalian glutamate transporters have been cloned. The extracellular levels of excitatory amino acids are kept low by the action of the glutamate transporters. Glutamate/aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) are the most abundant subtypes and are essential for the functioning of the mammalian CNS, but the contribution of the EAAC1 subtype in the clearance of synaptic glutamate has remained controversial, because the density of this transporter in different tissues has not been determined. Expression of short interfering RNA-mediated knockdown of RTN2B decreases the EAAC1 protein level in neurons."], "exact_answer": [["EAAC1", "EAAT3"], ["GLT-1", "glutamate transporter-1", "excitatory amino acid transporter 1"], ["GLAST", "Glutamate/aspartate transporter"], ["GluR4", "AMPA receptor glutamate receptor 4"], ["VGLUT1", "vesicular glutamate transporter"]], "type": "list", "id": "57169b63cb4ef8864c00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539860", "endSection": "title"}, {"offsetInBeginSection": 109, "offsetInEndSection": 470, "text": "Glutamate/aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) are the most abundant subtypes and are essential for the functioning of the mammalian CNS, but the contribution of the EAAC1 subtype in the clearance of synaptic glutamate has remained controversial, because the density of this transporter in different tissues has not been determined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539860", "endSection": "abstract"}, {"offsetInBeginSection": 657, "offsetInEndSection": 953, "text": "Using immunofluorescence and postembedding immunogold labeling, we investigated the distributions of the glutamate-aspartate transporter (GLAST or excitatory amino acid transporter 1), vesicular glutamate transporter (VGLUT1), and the AMPA receptor glutamate receptor 4 (GluR4) along the spiral. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14672993", "endSection": "abstract"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1710, "text": "Immunogold labeling for GluR4 was confined to synaptic sites, represented by puncta in immunofluorescence. The relative numbers of puncta changed with a gradient similar to that of GLAST labeling. VGLUT1 labeling occurred in IHCs but showed no clear cochleotopic gradient. These data suggest that both the density of innervation and the activity levels of glutamatergic synapses may be involved in modulating regional expression of GLAST.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14672993", "endSection": "abstract"}, {"offsetInBeginSection": 284, "offsetInEndSection": 449, "text": "In brain, EAAC1 (excitatory amino acid carrier 1) is the primary neuronal glutamate transporter, localized on the perisynaptic membranes that are near release sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18096700", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Reticulon RTN2B regulates trafficking and function of neuronal glutamate transporter EAAC1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18096700", "endSection": "title"}, {"offsetInBeginSection": 624, "offsetInEndSection": 747, "text": "Previously, we identified an EAAC1-associated protein, GTRAP3-18, an ER protein that prevents ER exit of EAAC1 when induced", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18096700", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 899, "text": "Here we show that RTN2B, a member of the reticulon protein family that mainly localizes in the ER and ER exit sites interacts with EAAC1 and GTRAP3-18", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18096700", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 355, "text": "In this study, uptake of L-[14C]cystine by three of the high affinity sodium-dependent mammalian glutamate transporters (GLT1, GLAST and EAAC1) individually expressed in HEK cells has been determined", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863236", "endSection": "abstract"}, {"offsetInBeginSection": 637, "offsetInEndSection": 942, "text": "Reduction of L-[14C]cystine to L-[14C]cysteine in the presence of 1mM cysteinylglycine increases the uptake rate in HEK(GLT1), HEK(GLAST) and HEK(EAAC1) cells, but only a small proportion (<10%) of L-[14C]cysteine uptake in HEK(GLT1) and HEK(GLAST) cells occurs by the high affinity glutamate transporters", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863236", "endSection": "abstract"}]}, {"body": "How is OCT3 associated with serotonin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23982114"], "ideal_answer": ["OCT3 plays a role in serotonin clearance"], "exact_answer": [["serotonin clearance"]], "type": "factoid", "id": "571e2beabb137a4b0c000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "The organic cation transporter 3 (OCT3) is a widely expressed transporter for endogenous and exogenous organic cations. Of particular interest is OCT3 expression and function in the brain, where it plays a role in serotonin clearance and influences mood and behavior. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23982114", "endSection": "abstract"}]}, {"body": "Which gene is involved in the development of Barth syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25941633", "http://www.ncbi.nlm.nih.gov/pubmed/25247053", "http://www.ncbi.nlm.nih.gov/pubmed/24813252"], "ideal_answer": ["Tafazzin, a mitochondrial acyltransferase encoded by a gene of the same name, plays an important role in cardiolipin side chain remodeling. Studies have shown that mutation-induced dysfunction of tafazzin reduces cardiolipin content, impairs mitochondrial function, and causes dilated cardiomyopathy in Barth syndrome (BTHS).", "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS)", "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS)", "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS)", "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS)", "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS)"], "exact_answer": [["Tafazzin (TAZ) gene"]], "type": "factoid", "id": "5717d86029809bbe7a000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941633", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 274, "text": "Tafazzin, a mitochondrial acyltransferase, plays an important role in cardiolipin side chain remodeling. Previous studies have shown that dysfunction of tafazzin reduces cardiolipin content, impairs mitochondrial function, and causes dilated cardiomyopathy in Barth syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25247053", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 422, "text": "we combined patient-derived and genetically engineered induced pluripotent stem cells (iPSCs) with tissue engineering to elucidate the pathophysiology underlying the cardiomyopathy of Barth syndrome (BTHS), a mitochondrial disorder caused by mutation of the gene encoding tafazzin (TAZ)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24813252", "endSection": "abstract"}]}, {"body": "What is the function of Neu5Gc (N-Glycolylneuraminic acid)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25124893", "http://www.ncbi.nlm.nih.gov/pubmed/23520510", "http://www.ncbi.nlm.nih.gov/pubmed/25003133", "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "http://www.ncbi.nlm.nih.gov/pubmed/23945141"], "ideal_answer": ["N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans.  Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. N-Glycolylneuraminic acid (Neu5Gc) can be incorporated in human cells and can trigger immune response, a response that is diverse and polyclonal. As dietary Neu5Gc is primarily found in red meat and milk products, it is suggested that this ongoing antigen-antibody reaction may generate chronic inflammation, possibly contributing to the high frequency of diet-related carcinomas and other diseases in humans."], "exact_answer": [["Neu5Gc is an immune message to self"]], "type": "factoid", "id": "5719f5b27de986d80d00000c", "snippets": [{"offsetInBeginSection": 77, "offsetInEndSection": 250, "text": "Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "N-glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23520510", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 195, "text": "N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. However, it can be incorporated in human cells and can trigger immune response.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25003133", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Human heterophile antibodies that agglutinate animal erythrocytes are known to detect the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 416, "text": " the human anti-Neu5Gc antibody response is diverse and polyclonal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "endSection": "abstract"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1677, "text": "As dietary Neu5Gc is primarily found in red meat and milk products, we suggest that this ongoing antigen-antibody reaction may generate chronic inflammation, possibly contributing to the high frequency of diet-related carcinomas and other diseases in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "endSection": "abstract"}, {"offsetInBeginSection": 974, "offsetInEndSection": 1247, "text": "These data suggest that anti-Neu5Gc Abs represent a barrier for long-term acceptance of porcine xenografts. Because anti-Neu5Gc Abs can promote chronic inflammation, the long-term safety of living and acellular pig tissue implants in recipients warrants further evaluation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945141", "endSection": "abstract"}]}, {"body": "Is SLC22A3 expressed in the brain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20402963"], "ideal_answer": ["Yes, SLC22A3 (organic cation transporter (OCT3)) is widely expressed in various organs in humans, and involved in the disposition of many exogenous and endogenous compounds. Several lines of evidence have suggested that OCT3 expressed in the brain plays an important role in the regulation of neurotransmission."], "exact_answer": "yes", "type": "yesno", "id": "571e3d42bb137a4b0c000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "The organic cation transporter (OCT) 3 is widely expressed in various organs in humans, and involved in the disposition of many exogenous and endogenous compounds. Several lines of evidence have suggested that OCT3 expressed in the brain plays an important role in the regulation of neurotransmission. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20402963", "endSection": "abstract"}]}, {"body": "Is Alpers disease inherited in an autosomal recessive mode?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22006280", "http://www.ncbi.nlm.nih.gov/pubmed/16181814", "http://www.ncbi.nlm.nih.gov/pubmed/15122711", "http://www.ncbi.nlm.nih.gov/pubmed/7897414"], "ideal_answer": ["Alpers disease is a fatal neurogenetic disorder first described more than 70 years ago. It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.", "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder", "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder", "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder", "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder", "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder"], "exact_answer": "yes", "type": "yesno", "id": "5718a69e7de986d80d00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22006280", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16181814", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 321, "text": "Alpers' syndrome is a fatal neurogenetic disorder first described more than 70 years ago. It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15122711", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 883, "text": "Histopathological findings in both patients ((a) chronic hepatitis with prominent bile duct proliferation, fatty change, and fibrosis; (b) in the brain a patchy destruction of the cerebral cortex, predominantly involving striate cortex) were characteristic of progressive neuronal degeneration of childhood with liver disease--Alpers-Huttenlocher syndrome--a rare autosomal recessive disorder usually seen in infants and young children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7897414", "endSection": "abstract"}]}, {"body": "What distinguishes lantibiotics from antibiotics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25787977", "http://www.ncbi.nlm.nih.gov/pubmed/23168402", "http://www.ncbi.nlm.nih.gov/pubmed/24069959", "http://www.ncbi.nlm.nih.gov/pubmed/24621781"], "ideal_answer": ["One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides. Low levels of resistance have been reported for lantibiotics compared with commercial antibiotics. Nisin is the oldest and the most widely used lantibiotic, in food preservation, without having developed any significant resistance against it.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "Lantibiotic compounds are ribosomally synthesized antimicrobial peptides against which bacteria are not able to produce resistance, hence making them a good alternative to antibiotics. It is interesting that low levels of resistance have been reported for lantibiotics compared with commercial antibiotics. Given that there are very few examples of naturally occurring lantibiotic resistance, attempts have been made to deliberately induce resistance phenotypes in order to investigate this phenomenon. Other general forms of resistance include the formation of spores or biofilms, which are a common mechanistic response to many classes of antimicrobials."], "exact_answer": [["Lantibiotics are post-translationally modified natural peptides containing lanthionine"]], "type": "factoid", "id": "5719f5c67de986d80d00000d", "snippets": [{"offsetInBeginSection": 124, "offsetInEndSection": 339, "text": "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787977", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 460, "text": "low levels of resistance have been reported for lantibiotics compared with commercial antibiotics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787977", "endSection": "abstract"}, {"offsetInBeginSection": 658, "offsetInEndSection": 877, "text": "Mechanisms that hinder the action of lantibiotics are often innate systems that react to the presence of any cationic peptides/proteins or ones which result from cell well damage, rather than being lantibiotic specific.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Lantibiotics are biologically active peptides produced by Gram-positive bacteria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23168402", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 269, "text": "Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a broad spectrum antimicrobial activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959", "endSection": "abstract"}, {"offsetInBeginSection": 103, "offsetInEndSection": 287, "text": "Lantibiotic compounds are ribosomally synthesized antimicrobial peptides against which bacteria are not able to produce resistance, hence making them a good alternative to antibiotics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781", "endSection": "abstract"}]}, {"body": "Are OATP1B1 and OATP1B3 associated with bilirubin transport?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23886114"], "ideal_answer": ["Yes, OATP1B1 and OATP1B3 are involved in the transport of bilirubin."], "exact_answer": "yes", "type": "yesno", "id": "571e3e2abb137a4b0c000008", "snippets": [{"offsetInBeginSection": 621, "offsetInEndSection": 811, "text": "OATP1B1 and OATP1B3-mediated transport of bilirubin was confirmed and inhibition was determined for atazanavir, rifampicin, indinavir, amprenavir, cyclosporine, rifamycin SV and saquinavir. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23886114", "endSection": "abstract"}]}, {"body": "Which currently known mitochondrial diseases have been attributed to POLG mutations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18546365"], "ideal_answer": ["Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO).", "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)"], "exact_answer": [["childhood Myocerebrohepatopathy Spectrum disorders (MCHS)"], ["Alpers syndrome"], ["Ataxia Neuropathy Spectrum (ANS) disorders"], ["Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA)"], ["autosomal recessive Progressive External Ophthalmoplegia (arPEO)"], ["autosomal dominant Progressive External Ophthalmoplegia (adPEO)"]], "type": "list", "id": "5718bbb37de986d80d00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 576, "text": "Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18546365", "endSection": "abstract"}]}, {"body": "Which syndrome is associated with OATP1B1 and OATP1B3 deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22232210"], "ideal_answer": ["Complete and simultaneous deficiency of the organic anion transporting polypeptides OATP1B1 and OATP1B3 due to mutations in their corresponding genes, has been linked to Rotor syndrome."], "exact_answer": [["Rotor syndrome"]], "type": "factoid", "id": "571e40a8bb137a4b0c000009", "snippets": [{"offsetInBeginSection": 518, "offsetInEndSection": 741, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}]}, {"body": "Which genes have been associated with Cerebral Cavernous Malformation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26246098", "http://www.ncbi.nlm.nih.gov/pubmed/24990152", "http://www.ncbi.nlm.nih.gov/pubmed/24466005", "http://www.ncbi.nlm.nih.gov/pubmed/24481819", "http://www.ncbi.nlm.nih.gov/pubmed/25451273"], "ideal_answer": ["Loss-of-function mutations in genes encoding CCM1 (also known as KRIT1), CCM2 (also known as OSM and malcavernin) or CCM3 (also known as PDCD10) cause cerebral cavernous malformations (CCMs)."], "exact_answer": [["CCM1/KRIT1"], ["CCM2/OSM/Malcavernin"], ["CCM3/PDCD10"]], "type": "list", "id": "571f2b5bbb137a4b0c000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Cerebral cavernous malformations associated to meningioma: High penetrance in a novel family mutated in the PDCD10 gene", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246098", "endSection": "title"}, {"offsetInBeginSection": 1041, "offsetInEndSection": 1150, "text": "we outline a consistent association between PDCD10 mutations and a syndrome of CCMs with multiple meningiomas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246098", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Cerebral cavernous malformation (CCM) is a disease of vascular malformations known to be caused by mutations in one of three genes: CCM1, CCM2 or CCM3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990152", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 189, "text": "To study the molecular genetic and clinical features of cerebral cavernous malformations (CCM) in a cohort of Spanish patients.METHODS: We analyzed the CCM1, CCM2, and CCM3 genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24466005", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Loss-of-function mutations in genes encoding KRIT1 (also known as CCM1), CCM2 (also known as OSM and malcavernin) or PDCD10 (also known as CCM3) cause cerebral cavernous malformations (CCMs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24481819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Surveying genetic variants and molecular phylogeny of cerebral cavernous malformation gene, CCM3/PDCD10", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451273", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "The three cerebral cavernous malformations (CCMs) genes namely CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 have been identified for which mutations cause cerebral cavernous malformations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451273", "endSection": "abstract"}]}, {"body": "What are the symptoms of Rotor syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22232210"], "ideal_answer": ["Rotor syndrome is characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics."], "exact_answer": [["conjugated hyperbilirubinemia"], ["coproporphyrinuria"], ["near-absent hepatic uptake of anionic diagnostics"]], "type": "list", "id": "571e417bbb137a4b0c00000a", "snippets": [{"offsetInBeginSection": 210, "offsetInEndSection": 518, "text": "The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}]}, {"body": "What is Cerebral Cavernous Malformation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26109568", "http://www.ncbi.nlm.nih.gov/pubmed/26523262", "http://www.ncbi.nlm.nih.gov/pubmed/24401931"], "ideal_answer": ["Cerebral cavernous malformations (CMs) are vascular malformations of the central nervous system, causing hemorrhagic strokes, seizures, and neurological deficits.", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences "], "type": "summary", "id": "571f2e8e0fd6f91b68000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26109568", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "Cerebral cavernous malformations (CMs) are vascular malformations of the central nervous system, which can be detected in the absence of any clinical symptoms. Nodules and cysts with mixed signal intensity and a peripheral hemosiderin rim are considered brain magnetic resonance imaging (MRI) findings typical of CMs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26523262", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 196, "text": "Cerebral cavernous malformations (CCM) are enlarged vascular lesions affecting 0.1-0.5% of the population worldwide and causing hemorrhagic strokes, seizures, and neurological deficits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24401931", "endSection": "abstract"}]}, {"body": "What is the cause of episodic ataxia type 6?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23107647"], "ideal_answer": ["Episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1. Reduced glutamate uptake by mutant excitatory amino acid transporter-1 (EAAT1) has been thought to be the main pathophysiological process in episodic ataxia type 6."], "exact_answer": [["EAAT1 mutations"]], "type": "factoid", "id": "571e4293bb137a4b0c00000b", "snippets": [{"offsetInBeginSection": 98, "offsetInEndSection": 497, "text": "There are several genetically and clinically distinct forms of this disease, and one of them, episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1. So far, reduced glutamate uptake by mutant excitatory amino acid transporter-1 has been thought to be the main pathophysiological process in episodic ataxia type 6. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}, {"offsetInBeginSection": 1645, "offsetInEndSection": 1934, "text": "Episodic ataxia type 6 represents the first human disease found to be associated with altered function of excitatory amino acid transporter anion channels and illustrates possible physiological and pathophysiological impacts of this functional mode of this class of glutamate transporters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}]}, {"body": "What is Sotos syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26043501", "http://www.ncbi.nlm.nih.gov/pubmed/25852445", "http://www.ncbi.nlm.nih.gov/pubmed/24670087"], "ideal_answer": ["Sotos syndrome is a rare genetic disorder with a distinct phenotypic spectrum including excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability.", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability"], "type": "summary", "id": "571f30c40fd6f91b68000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852445", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 133, "text": "Sotos syndrome is a rare genetic disorder with a distinct phenotypic spectrum including overgrowth and learning difficulties", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24670087", "endSection": "abstract"}]}, {"body": "Which gene has been associated with thyroid dyshormonogenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25465605"], "exact_answer": [[" "]], "type": "factoid", "id": "571e4523bb137a4b0c00000c", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 340, "text": "Dyshormonogenetic congenital hypothyroidism (CH) was reported to be associated with a mutation in the sodium iodide symporter (NIS) gene. The present study was undertaken in the Guangxi Zhuang Autonomous Region of China, to determine the nature and frequency of NIS gene mutations among patients with CH due to dyshormonogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465605", "endSection": "abstract"}]}, {"body": "Which gene is responsible for the development of Sotos syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26043501", "http://www.ncbi.nlm.nih.gov/pubmed/25852445"], "ideal_answer": ["Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability. Haploinsufficiency of the NSD1 gene at 5q35.3, arising from 5q35 microdeletions, point mutations, and partial gene deletions, accounts for a majority of patients with SoS.", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene"], "exact_answer": [["NSD1 gene"]], "type": "factoid", "id": "571f33bd0fd6f91b68000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability. Haploinsufficiency of the NSD1 gene at 5q35.3, arising from 5q35 microdeletions, point mutations, and partial gene deletions, accounts for a majority of patients with SoS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852445", "endSection": "abstract"}]}, {"body": "What are the characteristics of Christianson syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25044251"], "ideal_answer": ["Christianson syndrome (CS) is caused by mutations in the X-linked Na(+) /H(+) exchanger 6 (NHE6). Patients present with prominent neurological, medical, and behavioral symptoms. All CS participants were nonverbal and had intellectual disability, epilepsy, and ataxia. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%), and magnetic resonance imaging evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Medical symptoms, particularly gastrointestinal symptoms, are common. Height and body mass index measures were below normal ranges in most participants. Behavioral symptoms included hyperkinetic behavior (100%), and a majority exhibited high pain threshold."], "type": "summary", "id": "571e469bbb137a4b0c00000d", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 142, "text": "Recently, Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H(+) exchanger 6 (NHE6). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044251", "endSection": "abstract"}, {"offsetInBeginSection": 830, "offsetInEndSection": 1590, "text": "We also report prominent neurological, medical, and behavioral symptoms. All CS participants were nonverbal and had intellectual disability, epilepsy, and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%), and magnetic resonance imaging evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Medical symptoms, particularly gastrointestinal symptoms, were common. Height and body mass index measures were below normal ranges in most participants. Behavioral symptoms included hyperkinetic behavior (100%), and a majority exhibited high pain threshold.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044251", "endSection": "abstract"}]}, {"body": "Have 5q35 microdeletions been implicated in Sotos syndrome development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23913520", "http://www.ncbi.nlm.nih.gov/pubmed/12900893"], "ideal_answer": ["Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID).", "Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID)", "Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID)", "Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID)", "Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID)", "Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID)"], "exact_answer": "yes", "type": "yesno", "id": "571f33f10fd6f91b68000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "Loss-of-function mutations of NSD1 and 5q35 microdeletions encompassing NSD1 are a major cause of Sotos syndrome (Sos), which is characterized by overgrowth, macrocephaly, characteristic facies, and variable intellectual disability (ID)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913520", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 684, "text": "We observed a novel 3.5 Mb 5q subtelomeric deletion in a 3-year-old girl with developmental delay, hypotonia and multiple minor anomalies. Comparison of her phenotype with the few published patients with terminal 5q35 deletions revealed several overlapping features, but also showed remarkable differences such as shortness of stature versus macrosomia. After the report of 5q35.3 microdeletions in Sotos syndrome we integrated the published BACs into the public draft sequence and exactly mapped the deletion size in our patient by FISH analysis with 15 BAC probes. We demonstrated that the deletion in our patient is immediately adjacent to the reported Sotos syndrome deletion site", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12900893", "endSection": "abstract"}]}, {"body": "Is Weaver syndrome similar to Sotos?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24852293", "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "http://www.ncbi.nlm.nih.gov/pubmed/22287508"], "ideal_answer": ["Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap. NSD1 and EZH2 are SET domain-containing histone methyltransferases that play key roles in the regulation of transcription through histone modification and chromatin modeling.", "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes", "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes", "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes", "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes", "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes"], "exact_answer": "yes", "type": "yesno", "id": "571f34ac0fd6f91b68000005", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 439, "text": "Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24852293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 408, "text": "NSD1 and EZH2 are SET domain-containing histone methyltransferases that play key roles in the regulation of transcription through histone modification and chromatin modeling: NSD1 preferentially methylates lysine residue 36 of histone 3 (H3K36) and is primarily associated with active transcription, while EZH2 shows specificity for lysine residue 27 (H3K27) and is associated with transcriptional repression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 966, "text": "Constitutional NSD1 and EZH2 mutations cause Sotos and Weaver syndromes respectively, overgrowth syndromes with considerable phenotypic overlap", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23592277", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22287508", "endSection": "abstract"}]}, {"body": "What are the skeletal muscle satellite cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26074812", "http://www.ncbi.nlm.nih.gov/pubmed/25732238", "http://www.ncbi.nlm.nih.gov/pubmed/26341996", "http://www.ncbi.nlm.nih.gov/pubmed/26248268"], "ideal_answer": ["Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury.", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury"], "type": "summary", "id": "571f356f0fd6f91b68000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 454, "text": "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074812", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Satellite cells (SC) are quiescent adult muscle stem cells critical for postnatal development", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25732238", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Satellite cells are multipotential stem cells that mediate postnatal muscle growth and respond differently to temperature based upon aerobic versus anaerobic fiber-type origin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26341996", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 493, "text": "Skeletal muscle mass, function, and repair capacity all progressively decline with aging, restricting mobility, voluntary function, and quality of life. Skeletal muscle repair is facilitated by a population of dedicated muscle stem cells (MuSCs), also known as satellite cells, that reside in anatomically defined niches within muscle tissues. In adult tissues, MuSCs are retained in a quiescent state until they are primed to regenerate damaged muscle through cycles of self-renewal divisions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26248268", "endSection": "abstract"}]}, {"body": "Which are the common symptoms of Cushing's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24062268"], "ideal_answer": ["Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension."], "exact_answer": [["weight gain"], ["growth retardation"], ["hirsutism"], ["obesity"], ["striae"], ["acne"], ["hypertension"]], "type": "list", "id": "571f3b320fd6f91b68000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "Cushing syndrome is the constellation of signs and symptoms caused by protracted exposure to glucocorticoids. The most common cause of Cushing syndrome in children and adolescents is exogenous administration of glucocorticoids. Presenting features commonly include weight gain, growth retardation, hirsutism, obesity, striae, acne and hypertension", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24062268", "endSection": "abstract"}]}, {"body": "Is the Miller-Fisher syndrome considered to be a variant of Guillain-Barr\u00e9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26380131", "http://www.ncbi.nlm.nih.gov/pubmed/26366317", "http://www.ncbi.nlm.nih.gov/pubmed/24513384", "http://www.ncbi.nlm.nih.gov/pubmed/25072194"], "ideal_answer": ["Miller-Fisher syndrome is a variant of Guillain-Barr\u00e9 syndrome, characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia.", "Miller Fisher syndrome is a variant of Guillain-Barre syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia", "Miller Fisher syndrome is a variant of Guillain-Barre syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia", "Miller Fisher syndrome is a variant of Guillain-Barre syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia", "Miller Fisher syndrome is a variant of Guillain-Barre syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia", "Miller Fisher syndrome is a variant of Guillain-Barre syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia"], "exact_answer": "yes", "type": "yesno", "id": "571f59cd0fd6f91b68000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Miller Fisher syndrome is a variant of Guillain-Barre syndrome characterized by the classic triad of ophthalmoplegia, ataxia, and areflexia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380131", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 496, "text": "We are reporting a rare case of Miller-Fisher (MFS) variant of Guillain-Barr\u00e9 syndrome (GBS) as the first manifestation of SLE in a 41-year-old female", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26366317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Miller-Fisher syndrome is defined as ophthalmoplegia, ataxia and areflexia. Considered as a variant of Guillain-Barr\u00e9 syndrome, it differs in its clinical presentation and by anti-GQ1b antibody positivity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24513384", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Guillain-Barr\u00e9 syndrome (GBS) and its variant, Miller Fisher syndrome (MFS), exist as several clinical subtypes with different neurological features and presentations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25072194", "endSection": "abstract"}]}, {"body": "Which protein is found to be mutated in Friedreich's ataxia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25929520", "http://www.ncbi.nlm.nih.gov/pubmed/25597503", "http://www.ncbi.nlm.nih.gov/pubmed/25430730"], "ideal_answer": ["It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas.", "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas", "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas", "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas", "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas", "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas"], "exact_answer": [["Frataxin"]], "type": "factoid", "id": "571f5c150fd6f91b68000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly affects the brain, dorsal root ganglia of the spinal cord, heart and in certain cases the pancreas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25929520", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Friedreich's ataxia is a severe neurodegenerative disease caused by the decreased expression of frataxin, a mitochondrial protein that stimulates iron-sulfur (Fe-S) cluster biogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25597503", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "In eukaryotes, frataxin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (Fe-S) cluster protein activity, accumulation of mitochondrial iron and leads to the neurodegenerative disease Friedreich's ataxia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430730", "endSection": "abstract"}]}, {"body": "For which diseases members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24933366", "http://www.ncbi.nlm.nih.gov/pubmed/22973455", "http://www.ncbi.nlm.nih.gov/pubmed/21913121", "http://www.ncbi.nlm.nih.gov/pubmed/19778726"], "ideal_answer": ["Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD).", "Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)", "Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)", "Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)", "Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)", "Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)"], "exact_answer": [["Friedreich's ataxia (FRDA)"], ["Huntington's disease (HD)"]], "type": "list", "id": "571f5d3e0fd6f91b6800000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24933366", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 396, "text": "Histone deacetylase (HDAC) inhibitors have received considerable attention as potential therapeutics for a variety of cancers and neurological disorders. Recent publications on a class of pimelic diphenylamide HDAC inhibitors have highlighted their promise in the treatment of the neurodegenerative diseases Friedreich's ataxia and Huntington's disease, based on efficacy in cell and mouse models", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22973455", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 308, "text": "We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "We recently identified a class of pimelic diphenylamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19778726", "endSection": "abstract"}]}, {"body": "Which enzyme is deficient in Gaucher's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18627336", "http://www.ncbi.nlm.nih.gov/pubmed/18228687", "http://www.ncbi.nlm.nih.gov/pubmed/15453048", "http://www.ncbi.nlm.nih.gov/pubmed/12412377", "http://www.ncbi.nlm.nih.gov/pubmed/10155294"], "ideal_answer": ["Gaucher disease is an inborn recessive autosomal disease due to a partial deficiency of the lysosomal enzyme beta glucocerebrosidase. The deficient activity leads to accumulation of the lipid glucocerebroside in the liver, the spleen and bone marrow with concomitant anemia and thrombocytopenia.", "Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity", "Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity", "Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity", "Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity", "Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity"], "exact_answer": [["Beta glucocerebrosidase"]], "type": "factoid", "id": "571f5e740fd6f91b6800000b", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 90, "text": "Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18627336", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 373, "text": "Gaucher's disease is due to glucocerebrosidase deficiency which is responsible for the accumulation of non degraded glucosylceramide within the lysosomes of macrophages: these \"Gaucher cells\", overloaded and alternatively activated, release in patient's plasma numerous compounds (cytokines, chemokines, hydrolases...) some of which contribute to the various tissue damages", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228687", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Gaucher's disease is an uncommon inborn recessive autosomal disease, due to a deficient activity of the lysosomal enzyme beta glucocerebrosidase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15453048", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 294, "text": "Gaucher disease is an inborn recessive autosomal disease due to a partial deficiency of the lysosomal enzyme beta glucocerebrosidase. The deficient activity leads to accumulation of the lipid glucocerebroside in the liver, the spleen and bone marrow with concomitant anemia and thrombocytopenia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12412377", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Alglucerase is a modified form of human placental glucocerebrosidase used as enzyme replacement therapy for patients with Gaucher's disease, in whom functional glucocerebrosidase is deficient", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10155294", "endSection": "abstract"}]}, {"body": "Which enzyme deficiency can cause GM1 gangliosidoses?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23622392", "http://www.ncbi.nlm.nih.gov/pubmed/17442056", "http://www.ncbi.nlm.nih.gov/pubmed/1588015", "http://www.ncbi.nlm.nih.gov/pubmed/1909089", "http://www.ncbi.nlm.nih.gov/pubmed/2123760", "http://www.ncbi.nlm.nih.gov/pubmed/2117086"], "ideal_answer": ["GM1 gangliosidoses are associated with deficiency of \u03b2-galactosidase."], "exact_answer": [["\u03b2-galactosidase"]], "type": "factoid", "id": "571f609c0fd6f91b6800000c", "snippets": [{"offsetInBeginSection": 272, "offsetInEndSection": 382, "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23622392", "endSection": "abstract"}, {"offsetInBeginSection": 89, "offsetInEndSection": 257, "text": "The total content and distribution of retinal glycosphingolipids was studied for the first time in control mice and in Sandhoff disease (SD) and GM1 gangliosidosis mice", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17442056", "endSection": "abstract"}, {"offsetInBeginSection": 896, "offsetInEndSection": 1056, "text": "The GSL abnormalities in the SD and the GM1 retinas reflect significant reductions in beta-hexosaminidase and beta-galactosidase enzyme activities, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17442056", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 911, "text": "In the absence of macular or retinal degeneration, organomegaly, and somatic-facial features suggesting mucopolysaccharidosis, the presence of hyperacusis together with sea-blue histiocytes in bone marrow biopsies and deficient beta-galactosidase activity but normal glucosidase, hexosaminidase, and neuraminidase activity on lysosomal enzyme assays constitutes the clinical-pathologic-biochemical profile of GM1 gangliosidosis type 2. This is a rare, late infantile onset, progressive gray-matter disease in which beta-galactosidase deficiency is largely localized to the brain, though it can be demonstrated in leukocytes and cultured skin fibroblasts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1588015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "GM1-gangliosidosis (genetic beta-galactosidase deficiency)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1909089", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "GM1-gangliosidosis is a genetic neurological disorder caused by mutations in the lysosomal acid beta-galactosidase gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1909089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "GM1-gangliosidosis is a rare neurovisceral storage disease caused by an inherited deficiency of acid beta-galactosidase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2123760", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "A female infant with early-onset GM1-gangliosidosis type I was investigated. The lymphocytes, transformed lymphocytes and cultured skin fibroblasts of the patient were demonstrated to have severe beta-D-galactosidase deficiency", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2117086", "endSection": "abstract"}]}, {"body": "Which gene is involved in Giant Axonal Neuropathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25398950", "http://www.ncbi.nlm.nih.gov/pubmed/24211141", "http://www.ncbi.nlm.nih.gov/pubmed/23890932", "http://www.ncbi.nlm.nih.gov/pubmed/24273072", "http://www.ncbi.nlm.nih.gov/pubmed/24947478"], "ideal_answer": ["Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene, resulting in a loss of a ubiquitously expressed protein, gigaxonin.", "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin", "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin", "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin", "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin", "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin"], "exact_answer": [["GAN gene"]], "type": "factoid", "id": "572096c90fd6f91b6800000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398950", "endSection": "abstract"}, {"offsetInBeginSection": 224, "offsetInEndSection": 464, "text": "We describe a toddler with clinical features suggesting giant axonal neuropathy (GAN), whose diagnosis was confirmed by minimally invasive skin biopsy and corroborated by the finding of compound heterozygous mutations involving the GAN gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24211141", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Giant Axonal Neuropathy is a pediatric neurodegenerative disorder caused by autosomal recessive mutations in the GAN gene on chromosome 16q24.1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890932", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 136, "text": "Giant axonal neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder caused by mutations in the GAN gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24273072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 335, "text": "Giant axonal neuropathy (GAN) is a rare pediatric neurodegenerative disease. It is best known for the \"giant\" axons caused by accumulations of intermediate filaments. The disease is progressive, with onset around age 3 years and death by the third decade of life. GAN results from recessive mutations in the GAN gene encoding gigaxonin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24947478", "endSection": "abstract"}]}, {"body": "Is acid alpha-glucosidase the enzyme that causes Pompe disease when mutant?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26029718", "http://www.ncbi.nlm.nih.gov/pubmed/25217571", "http://www.ncbi.nlm.nih.gov/pubmed/25256446", "http://www.ncbi.nlm.nih.gov/pubmed/25786784"], "ideal_answer": ["Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme acid \u03b1-glucosidase (GAA), responsible for degradation of lysosomal glycogen.", "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))", "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))", "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))", "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))", "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))"], "exact_answer": "yes", "type": "yesno", "id": "572099930fd6f91b6800000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid \u03b1-glucosidase (GAA))", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Pompe disease is a systemic metabolic disorder characterized by lack of acid-alpha glucosidase (GAA) resulting in ubiquitous lysosomal glycogen accumulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217571", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Pompe disease is an autosomal recessive myopathic disorder caused by the deficiency of lysosomal acid \u03b1-glucosidase (GAA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256446", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 142, "text": "Acid \u03b1-glucosidase deficiency, that is, Pompe disease, is a glycogenosis for which enzyme replacement therapy (ERT) is available", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786784", "endSection": "abstract"}]}, {"body": "Which could be some of the possible causes of hypersomnia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17584779", "http://www.ncbi.nlm.nih.gov/pubmed/11022396", "http://www.ncbi.nlm.nih.gov/pubmed/9381026", "http://www.ncbi.nlm.nih.gov/pubmed/8491310"], "ideal_answer": ["Sleep-wake disturbances (SWD) with hypersomnia are common after traumatic brain injury (TBI), with decreased CSF levels of hypocretin-1, a wake-promoting neurotransmitter, in cases of sleep apnea, as well as in up to half the patients with dementia, particularly in vascular dementia, Korsakow syndrome, Parkinson's disease, and depression, where the alteration of sleep architecture may be pronounced, whereas in Alzheimer's disease prominent hypersomnolence or insomnia is typically only found in later stages of the diseases."], "exact_answer": [["traumatic brain injury (TBI)"], ["sleep apnea"], ["dementia"]], "type": "list", "id": "5720a8da0fd6f91b68000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Sleep-wake disturbances (SWD) are common after traumatic brain injury (TBI). In acute TBI, we recently found decreased CSF levels of hypocretin-1, a wake-promoting neurotransmitter", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584779", "endSection": "abstract"}, {"offsetInBeginSection": 1833, "offsetInEndSection": 1930, "text": "Hypocretin levels 6 months after TBI were significantly lower in patients with post-traumatic EDS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584779", "endSection": "abstract"}, {"offsetInBeginSection": 2178, "offsetInEndSection": 2334, "text": "These results suggest that sleep-wake disturbances, particularly EDS, fatigue and hypersomnia are common after TBI, and significantly impair quality of life", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584779", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "When sleepiness is excessive, undesirable, inappropriate or unexplained, it often indicates a clinical disorder that is generically termed hypersomnia. One of the leading causes of hypersomnia is sleep apnea", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11022396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 583, "text": "A clinically relevant sleep-wake disturbance is found in up to half the patients with dementia, and the sundowning agitation is a common cause of institutionalisation of demented geriatric patients. The circadian rhythm of demented patients is levelled off with increased daytime sleep and disrupted night sleep. Particularly in vascular dementia, Korsakow syndrome, Parkinson's disease, and depression the alteration of sleep architecture may be pronounced, whereas in Alzheimer's disease prominent hypersomnolence or insomnia is typically only found in later stages of the diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9381026", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "We report on an 83 yr old man with hypersomnia and central sleep apnoea (CSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8491310", "endSection": "abstract"}]}, {"body": "Which inherited disorder is known to be caused by mutations in the NEMO gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22036144", "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "http://www.ncbi.nlm.nih.gov/pubmed/17569396", "http://www.ncbi.nlm.nih.gov/pubmed/16104114"], "ideal_answer": ["Incontinentia pigmenti (IP) or Bloch-Sulzberger syndrome (BSS) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait.", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait"], "exact_answer": [["Incontinentia pigmenti or Bloch-Sulzberger syndrome"]], "type": "factoid", "id": "5721f4b30fd6f91b68000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22036144", "endSection": "abstract"}, {"offsetInBeginSection": 615, "offsetInEndSection": 754, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "De novo NEMO gene deletion (delta4-10)--a cause of incontinentia pigmenti in a female infant", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Incontinentia pigmenti (IP) is a rare, inherited, multisystem genodermatosis. It is transmitted as an X-linked dominant trait. The disorder is a consequence of mutations in the NEMO gene (Xq28) that completely abolish expression of the NF-kappaB essential modulator", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 536, "text": "Incontinentia pigmenti (IP) is a rare inherited multisystem disorder characterized by a distinctive swirling pattern of the skin; defects of teeth, hair, and nails; and ophthalmic, central nervous system, and musculoskeletal abnormalities. It progresses through several well-defined stages. IP is transmitted as a dominant X-linked trait with variable expressivity, but many--if not most--cases are sporadic. IP has been shown to result from mutations in the NEMO gene that completely abolish expression of NF-kappaB essential modulator", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Incontinentia pigmenti (IP; MIM308310) is a rare neurocutaneous X-dominant inherited disorder. Besides skin and neurological abnormalities, there is also ophthalmologic and dental involvement", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16104114", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 866, "text": "The disorder is observed almost exclusively in girls, but diseased boys are more seriously affected. The IP gene is localised on chromosome Xq28. Mutations in the NEMO-gene are responsible for IP. This gene codes for the nuclear factor-KB essential modulator protein (NEMO; synonym: inhibitor kappaB kinase (IKK)y)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16104114", "endSection": "abstract"}]}, {"body": "Are seizures among the neurological symptoms of incontinentia pigmenti?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24682289", "http://www.ncbi.nlm.nih.gov/pubmed/25238668", "http://www.ncbi.nlm.nih.gov/pubmed/23622185", "http://www.ncbi.nlm.nih.gov/pubmed/22564885"], "ideal_answer": ["Incontinentia pigmenti is an X-linked dominant disorder resulting from a mutation of IKBKG. This disorder has a classic dermatologic presentation, but neurologic involvement, with seizures and cortical infarction, can arise shortly after birth."], "exact_answer": "yes", "type": "yesno", "id": "5721f6f90fd6f91b68000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "High-dose glucocorticoid therapy in the management of seizures in neonatal incontinentia pigmenti", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682289", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "Incontinentia pigmenti is an X-linked dominant disorder resulting from a mutation of IKBKG. This disorder has a classic dermatologic presentation, but neurologic involvement, with seizures and cortical infarction, can arise shortly after birth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682289", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 189, "text": "Some children with incontinentia pigmenti exhibit encephalopathic features with severe seizures and disturbed consciousness, from the neonatal through the early infantile period", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238668", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 808, "text": "Incontinentia pigmenti (IP) is a rare X-linked dominant neurocutaneous disorder affecting ectodermal tissue: skin, eyes, central nervous system, hair, nails, and teeth. It is usually lethal for males in utero. The involved gene is NEMO, an essential component of the nuclear factor-kappa B (NF-\u03baB) signaling pathway. Skin lesions are highly diagnostic, occurring in neonates, with a particular distribution on Blaschko lines. The severity of the disease is related to ocular and neurological impairment. The hallmark of ocular IP is retinal vasculopathy including peripheral retinal vascular nonperfusion, macular infarction and neovascularization, and preretinal neovascularization. CNS involvement consists of seizures, mental retardation, hemiparesis, spasticity, microcephaly, cerebellar ataxia, and coma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23622185", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 525, "text": "Incontinentia Pigmenti is a rare X-linked multisystem disorder with well described and pathognomonic skin manifestations. Neurological manifestations are found in 30% of IP patients, forming one of the major causes of morbidity and mortality of the condition. In this review, clinical and brain imaging data of 45 IP patients with a neurological phenotype are reviewed. Several clinical presentations could be identified, comprising seizures, infantile encephalopathy, acute disseminated encephalomyelitis and ischemic stroke", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564885", "endSection": "abstract"}]}, {"body": "Which is the most common genetic lesion among patients with Joubert Syndrome and a cerebello-oculo-renal phenotype?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24946806"], "ideal_answer": ["Joubert syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP with cerebellar vermis aplasia and retinal degeneration. Among patients with JBTS and a cerebello-oculo-renal phenotype, mutations in CEP290 (NPHP6) are the most common genetic lesion.", "Nephronophthisis (NPHP) is the major cause of pediatric renal failure, yet the disease remains poorly understood, partly due to the lack of appropriate animal models. Joubert syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP with cerebellar vermis aplasia and retinal degeneration. Among patients with JBTS and a cerebello-oculo-renal phenotype, mutations in CEP290 (NPHP6) are the most common genetic lesion", "Nephronophthisis (NPHP) is the major cause of pediatric renal failure, yet the disease remains poorly understood, partly due to the lack of appropriate animal models. Joubert syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP with cerebellar vermis aplasia and retinal degeneration. Among patients with JBTS and a cerebello-oculo-renal phenotype, mutations in CEP290 (NPHP6) are the most common genetic lesion", "Nephronophthisis (NPHP) is the major cause of pediatric renal failure, yet the disease remains poorly understood, partly due to the lack of appropriate animal models. Joubert syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP with cerebellar vermis aplasia and retinal degeneration. Among patients with JBTS and a cerebello-oculo-renal phenotype, mutations in CEP290 (NPHP6) are the most common genetic lesion", "Nephronophthisis (NPHP) is the major cause of pediatric renal failure, yet the disease remains poorly understood, partly due to the lack of appropriate animal models. Joubert syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP with cerebellar vermis aplasia and retinal degeneration. Among patients with JBTS and a cerebello-oculo-renal phenotype, mutations in CEP290 (NPHP6) are the most common genetic lesion"], "type": "summary", "id": "5722027a0fd6f91b68000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 421, "text": "Nephronophthisis (NPHP) is the major cause of pediatric renal failure, yet the disease remains poorly understood, partly due to the lack of appropriate animal models. Joubert syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP with cerebellar vermis aplasia and retinal degeneration. Among patients with JBTS and a cerebello-oculo-renal phenotype, mutations in CEP290 (NPHP6) are the most common genetic lesion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24946806", "endSection": "abstract"}]}, {"body": "Which are the most common symptoms in Lambert-Eaton Myasthenic Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24114606", "http://www.ncbi.nlm.nih.gov/pubmed/24481713", "http://www.ncbi.nlm.nih.gov/pubmed/21822385"], "ideal_answer": ["Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms, that may include dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer, and the other that is a pure autoimmune form.", "Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome)", "Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome)", "Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome)", "Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome)", "Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome)"], "exact_answer": [["proximal limb muscle weakness"], ["fatigability"], ["decreased deep-tendon reflexes"], ["autonomic symptoms"], ["small-cell lung cancer"]], "type": "list", "id": "57220e400fd6f91b68000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 425, "text": "Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114606", "endSection": "abstract"}, {"offsetInBeginSection": 368, "offsetInEndSection": 878, "text": "LEMS weakness typically involves lower and upper limbs and the proximal muscles are predominantly affected. A significant proportion of patients also have dysfunction of the autonomic nervous system that may include dry mouth, constipation, blurred vision, impaired sweating, and orthostatic hypotension. LEMS recognition is based on clinical, electrophysiological and immunological criteria. Nearly 50-60% of patients with LEMS have an underlying tumour that, in almost all cases, is a small-cell lung cancer;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24481713", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "In Lambert-Eaton myasthenic syndrome (LEMS), antibodies against presynaptic voltage-gated calcium channels reduce the quantal release of acetylcholine, causing muscle weakness and autonomic dysfunction. More than half of the affected patients have associated small cell lung cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21822385", "endSection": "abstract"}]}, {"body": "Can vitamin B1 deficiency cause encephalopathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25050351", "http://www.ncbi.nlm.nih.gov/pubmed/24379094", "http://www.ncbi.nlm.nih.gov/pubmed/24701066", "http://www.ncbi.nlm.nih.gov/pubmed/25515801"], "ideal_answer": ["Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia. It is commonly associated with heavy alcohol consumption. Other clinical associations are with hyperemesis gravidarum (HG), starvation, and prolonged intravenous feeding.", "Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia", "Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia", "Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia", "Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia", "Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia"], "exact_answer": "yes", "type": "yesno", "id": "572211540fd6f91b68000016", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050351", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Wernicke encephalopathy (or Wernicke-Korsakoff encephalopathy) is a rarely diagnosed neurological disorder, which is caused by vitamin B1 deficiency", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379094", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Wernicke's encephalopathy (WE) is a potentially reversible yet serious neurological manifestation caused by vitamin B1(thiamine) deficiency", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701066", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 81, "text": "Wernicke encephalopathy is caused by thiamine (vitamin B1) deficiency", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25515801", "endSection": "abstract"}]}, {"body": "Which intraflagellar transport (IFT) motor protein has been linked to human skeletal ciliopathies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25470043", "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "http://www.ncbi.nlm.nih.gov/pubmed/24183451"], "ideal_answer": ["Intraflagellar transport (IFT) depends on two evolutionarily conserved modules, subcomplexes A (IFT-A) and B (IFT-B), to drive ciliary assembly and maintenance. All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies"], "exact_answer": [["Intraflagellar transport (IFT) motor protein DYNC2H1"]], "type": "factoid", "id": "57279ef20fd6f91b68000018", "snippets": [{"offsetInBeginSection": 295, "offsetInEndSection": 411, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 408, "text": "Intraflagellar transport (IFT) depends on two evolutionarily conserved modules, subcomplexes A (IFT-A) and B (IFT-B), to drive ciliary assembly and maintenance. All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 525, "text": "Bidirectional (anterograde and retrograde) motor-based intraflagellar transport (IFT) governs cargo transport and delivery processes that are essential for primary cilia growth and maintenance and for hedgehog signaling functions. The IFT dynein-2 motor complex that regulates ciliary retrograde protein transport contains a heavy chain dynein ATPase/motor subunit, DYNC2H1, along with other less well functionally defined subunits. Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}]}, {"body": "Which gene has been found to be mutant in Lesch-Nyhan Disease patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24075303", "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "http://www.ncbi.nlm.nih.gov/pubmed/23691025", "http://www.ncbi.nlm.nih.gov/pubmed/22157001", "http://www.ncbi.nlm.nih.gov/pubmed/20159777"], "ideal_answer": ["Lesch-Nyhan Disease (LND) is the result of mutations in the X-linked gene encoding the purine metabolic enzyme, hypoxanthine guanine phosphoribosyl transferase (HPRT)."], "exact_answer": [["Hypoxanthine guanine phosphoribosyl transferase (HPRT) gene"]], "type": "factoid", "id": "5727ab040fd6f91b68000019", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "We describe a family of seven boys affected by Lesch-Nyhan disease with various phenotypes. Further investigations revealed a mutation c.203T>C in the gene encoding HGprt of all members, with substitution of leucine to proline at residue 68 (p.Leu68Pro)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24075303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Lesch-Nyhan disease (LND) is caused by deficiency of hypoxanthine guanine phosphoribosyltransferase (HPRT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Lesch-Nyhan Disease (LND) is the result of mutations in the X-linked gene encoding the purine metabolic enzyme, hypoxanthine guanine phosphoribosyl transferase (HPRT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23691025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Lesch-Nyhan disease and its attenuated variants are caused by mutations in the HPRT1 gene, which encodes the purine recycling enzyme hypoxanthine-guanine phosphoribosyltransferase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 421, "text": "The study of Lesch-Nyhan-diseased (LND) human brain is crucial for understanding how mutant hypoxanthine-phosphoribosyltransferase (HPRT) might lead to neuronal dysfunction. Since LND is a rare, inherited disorder caused by a deficiency of the enzyme HPRT, human neural stem cells (hNSCs) that carry this mutation are a precious source for delineating the consequences of HPRT deficiency and for developing new treatments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20159777", "endSection": "abstract"}]}, {"body": "Is autism one of the characteristics of Moebius syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22832772", "http://www.ncbi.nlm.nih.gov/pubmed/19255803", "http://www.ncbi.nlm.nih.gov/pubmed/15736079", "http://www.ncbi.nlm.nih.gov/pubmed/2929356"], "ideal_answer": ["Moebius syndrome is a rare congenital disorder usually defined as a combination of facial weakness with impairment of ocular abduction. A strong association of Moebius syndrome with autism spectrum disorders (ASDs) has been suggested in early studies with heterogenous age groups."], "exact_answer": "yes", "type": "yesno", "id": "5727b6410fd6f91b6800001b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 410, "text": "The diagnosis of Moebius syndrome, a rare congenital disorder, is primarily based on congenital facial and abducent nerve palsy. Involvement of other cranial nerves is also common. Occasionally the V, X, XI, and XII cranial nerves are involved, resulting in a difficulty to chew, swallow, and cough, which often leads to respiratory complications. Mental retardation and autism have been reported in some cases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22832772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Moebius sequence is a rare congenital disorder usually defined as a combination of facial weakness with impairment of ocular abduction. A strong association of Moebius sequence with autism spectrum disorders (ASDs) has been suggested in earlier studies with heterogenous age groups", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 1069, "text": "Certain genetic syndromes are providing us with extremely valuable information about the role played by genetics in autism. This is the case of the following syndromes: Angelman syndrome, Prader-Willi syndrome, 15q11-q13 duplication, fragile X syndrome, fragile X premutation, deletion of chromosome 2q, XYY syndrome, Smith-Lemli-Opitz syndrome, Apert syndrome, mutations in the ARX gene, De Lange syndrome, Smith-Magenis syndrome, Williams syndrome, Rett syndrome, Noonan syndrome, Down syndrome, velo-cardio-facial syndrome, myotonic dystrophy, Steinert disease, tuberous sclerosis, Duchenne's disease, Timothy syndrome, 10p terminal deletion, Cowden syndrome, 45,X/46,XY mosaicism, Myhre syndrome, Sotos syndrome, Cohen syndrome, Goldenhar syndrome, Joubert syndrome, Lujan-Fryns syndrome, Moebius syndrome, hypomelanosis of Ito, neurofibromatosis type 1, CHARGE syndrome and HEADD syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15736079", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Seventeen children and young adults with Moebius syndrome were examined with a view to finding symptoms of autism. Some 40% of the group showed all or many of the symptoms typical of autistic disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356", "endSection": "abstract"}]}]}